TITLE:

N-Heterocyclic Carbene-Catalyzed Benzoin Strategy for Divergent Synthesis of Cyclitol Derivatives from Alditols

AUTHOR(S):

Kang, Bubwoong; Sutou, Toshiaki; Wang, Yinli; Kuwano, Satoru; Yamaoka, Yousuke; Takasu, Kiyosei; Yamada, Ken-ichi

CITATION:

Kang, Bubwoong ...[et al]. N-Heterocyclic Carbene-Catalyzed Benzoin Strategy for Divergent Synthesis of Cyclitol Derivatives from Alditols. *Advanced Synthesis & Catalysis* 2014, 357(1): 131-147

ISSUE DATE:

2014-12-08

URL:

<http://hdl.handle.net/2433/200181>

RIGHT:

This is the peer reviewed version of the following article: Kang, B., Sutou, T., Wang, Y., Kuwano, S., Yamaoka, Y., Takasu, K. and Yamada, K.-i. (2015), N-Heterocyclic Carbene-Catalyzed Benzoin Strategy for Divergent Synthesis of Cyclitol Derivatives from Alditols. *Adv. Synth. Catal.*, 357: 131-147, which has been published in final form at <http://dx.doi.org/10.1002/adsc.201400712>. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving; The full-text file will be made open to the public on 8 DEC 2015 in accordance with publisher's 'Terms and Conditions for Self-Archiving'; This is not the published version. Please cite only the published version.; この論文は出版社版ではありません。引用の際には出版社版をご確認ご利用ください。

DOI: 10.1002/adsc.201((will be filled in by the editorial staff))

N-Heterocyclic Carbene-Catalyzed Benzoin Strategy for Divergent Synthesis of Cyclitol Derivatives from Alditols

Bubwoong Kang,^a Toshiaki Sutou,^a Yinli Wang,^a Satoru Kuwano,^a Yousuke Yamaoka,^a Kiyosei Takasu,^{a*} and Ken-ichi Yamada^{a*}

^a Graduate School of Pharmaceutical Sciences, Kyoto University, Yoshida, Sakyo-ku, Kyoto 606-8501, Japan
Phone: +81-(0)75-753-4573. E-mail: kay-t@pharm.kyoto-u.ac.jp, yamak@pharm.kyoto-u.ac.jp

Received: ((will be filled in by the editorial staff))

Supporting information for this article is available on the WWW under <http://dx.doi.org/10.1002/adsc.201#####>. ((Please delete if not appropriate))

Abstract. A divergent synthesis of cyclitol derivatives has been developed utilizing N-heterocyclic carbene-catalyzed benzoin-type cyclization of C_2 -symmetric dialdoses. The resulting inososes are versatile intermediates, which are readily converted into not only inositols but also amino-, deoxy-, *O*-methyl-, and *C*-methyl-inositols.

Keywords: N-heterocyclic carbenes; a benzoin reaction; cyclitol derivatives

Introduction

Cyclitols, which are poly-hydroxylated cycloalkanes, have attracted attention, especially as building blocks for natural product synthesis.^[1] In addition, interesting bioactivities of cyclitols have recently been reported.^[2] Despite the utilities, cyclitols are not readily available in nature. Hence, many synthetic methods have been developed.^[3] In addition to fermentative approaches,^[4] various reactions have been applied to make cycloalkanes from oxygenated carbon chains, including Ferrier carbocyclization,^[5] cyclization of malonates,^[6] nitronate,^[7] enolate,^[8] or α,α -dithio carbanion,^[9] Mukaiyama aldol reactions,^[10] Horner–Wadsworth–Emmons reactions,^[11] pinacol coupling,^[12] and ring-closing metathesis,^[13] cycloaddition,^[14] and Claisen rearrangement.^[15]

The benzoin condensation, which occurs between two molecules of aldehydes to give α -hydroxy ketones,^[16] is a well-known N-heterocyclic carbene (NHC)-catalyzed reaction.^[17,18] Because the products are simple homo-dimeric compounds, the original reaction has a limited utility. Therefore, efforts have been made to develop the so-called cross-benzoin reactions. In particular, an intramolecular cross-benzoin reaction between aldehydes and ketones^[19] has been utilized for natural product synthesis.^[20] In contrast, an intramolecular benzoin reaction of dialdehydes has been less explored,^[21] probably due to difficulty in controlling chemoselectivity^[22] and the lack of attention to products derived from simple symmetric dialdehydes.^[19c,23] However, we expected that an intramolecular benzoin-type cyclization of dialdose should provide a new divergent access to a variety of cyclitol derivatives.

Our strategy is based on the availability of various dialdoses **1** and the versatility of inososes **2** as a synthetic intermediate (Scheme 1). Benzoin-type cyclization of **1**, which is available from the corresponding alditols, should give **2**. Stereoselective reduction of **2** affords cyclitols **3** and *epi*-**3**. Moreover, other derivatives, such as amino, deoxy, and *O*- and *C*-methyl cyclitols **4**, **5**, **6**, and **7** should also be available from **2**. Herein, we report the syntheses of cyclitol derivatives based on this strategy using C_2 -symmetric dialdoses.^[24]

Scheme 1. Divergent strategy for cyclitol derivatives via NHC-catalyzed benzoin-type cyclization.

Results and Discussion

NHC-catalyzed benzoin-type cyclization of C_2 -symmetric dialdoses to give inososes

First, tetrabenzyl dialdose **1a**, which was prepared from D-mannitol, was subjected to an NHC-catalyzed benzoin-type cyclization reaction (Table 1). A THF solution of **1a** was added to a solution of thiazolium salt **8**^[25] (Figure 1; 25 mol %) and triethylamine (20 mol %) in THF. After stirring at rt for 4 h, TLC monitoring indicated that **1a** was completely consumed, and *allo*-2-inosose **2a** was produced as a single diastereomer in 19% yield after purification by silica gel column chromatography (entry 1).^[26] The stereochemistry of the newly formed hydroxyl group was determined by the *trans*-diaxial coupling ($J = 9.5$ Hz)^[27] between the carbinol and the adjacent methine protons (H_5 and H_6 ; Figure 2).

Using triazolium salt **9a**^[28] or **9b**^[29] instead of **8** gave a complex mixture, and **2a** was not obtained (entries 2 and 3). Because several formyl protons were observed in ¹H NMR of the crude mixtures, it is speculated that aldol-type side reactions occur due to the basicity of the utilized NHCs. Using more acidic triazolium salt **9c**^[28] with a pentafluorophenyl group suppressed the side reactions, and **2a** was obtained in 58% yield after 10 h (entry 4).

To our delight, using chiral triazolium salt **10**^[28] drastically accelerated the reaction, which was completed after 2.5 h even with a lower catalyst loading (10 mol %) and an improved yield of **2a** (78%) (entry 5). Interestingly, when the antipode of **10** was used as a catalyst, the reaction did not proceed, and **1a** was recovered quantitatively after 24 h (entry 6).

Table 1. Optimization of the reaction conditions for **1a**^a

entry	NHC·HX	solvent	time/h	yield/% ^b
1	8 25 mol %	THF	4	19
2	9a 25 mol %	THF	24	<1
3	9b 25 mol % ^c	THF	24	<1
4	9c 25 mol %	THF	10	58
5	10 10 mol %	THF	2.5	78
6	<i>ent</i> - 10 25 mol %	THF	24	0 (quant)
7	10 5 mol %	THF	24	39 (11)
8	10 5 mol %	MeCN	12	83
9	10 5 mol %	CH ₂ Cl ₂	0.5	81
10	10 5 mol %	toluene	0.75	88
11 ^d	10 5 mol %	toluene	1	90

^a 20 mol % of Et₃N was used in entries 1–4 and 6, while same amount of Et₃N as NHC·HX was used in entries 5 and 7–11. ^b **1a** was completely consumed unless the recovery yield is presented in parentheses. ^c DBU was used instead of Et₃N. ^d 6.0 g of **1a** (11 mmol) was used.

Figure 1. Structures of the NHC precursors.

Figure 2. Determination of the stereochemistry of inososes.

Other solvents were tested for the reaction using 5 mol % of **10**. In acetonitrile, the reaction proceeded more cleanly, and **2a** was obtained in a higher yield (83% after 12 h; entry 8) than that in THF (39% after 24 h; entry 7). The reaction was much faster in dichloromethane, and **2a** was obtained in 81% yield after 30 min (entry 9). Among the tested solvents, toluene gave the best results (88% yield after 45 min; entry 10). It is noteworthy that the reaction with 6.0-g **1a** proceeded without problems to give 5.4-g **2a** (entry 11).

Next, the reaction was conducted with another C₂-symmetric dialdose **1b**, which was derived from L-idoitol (Scheme 2). Although the reaction with **9c** gave **2b** in a moderate yield along with unidentified byproducts, the reaction with *ent*-**10** (10 mol %) afforded *myo*-inosose **2b** as a single diastereomer in 86% yield. In contrast to the reaction with **1a**, which has the opposite stereochemistry at the α-positions, **1b** and **10** had a mismatched stereochemistry, giving **2b** in 58% yield after 24 h along with 27% recovery of **1b**. The stereochemistry of **2b** was determined based on the coupling constant similar to that of **2a** (Figure 2).

Scheme 2. Reaction with **1b**.

The observed stereoselectivity in the benzoin-type cyclization of dialdoses **1a** and **1b** can be explained as follows (Scheme 3; for simplicity, *ent*-**1b** and **10** are considered instead of **1b** and *ent*-**10**). Breslow intermediate **A**,^[18] which is generated from **10** and dialdose **1a** or *ent*-**1b**, undergoes cyclization through the chair conformation, where the benzyloxy group next to the nucleophilic enamine carbon is in the equatorial position to minimize A^{1,3} strain. The nucleophilic attack then occurs from the *si*-face of the aldehyde moiety, which leads to hydrogen bonding between the carbonyl and the hydroxy group,

resulting in the *R*-configuration in the newly formed stereochemistry.

The observed stereochemical outcome and match-mismatch with **10** and *ent*-**10** likely indicate that the reaction better proceeds through the Breslow intermediate with the *Z*-geometry; otherwise the reaction would occur from the hindered face of the enamine moiety. This model contradicts the Houk's model, where a Breslow intermediate derived from *N*-phenyl triazolyldene prefers the *E*-geometry in the transition state of a benzoin reaction.^[30] Recently, however, Rovis' group also reported evidence of the *Z*-preference for a Breslow intermediate derived from *N*-pentafluorophenyl triazolyldene.^[31] The preferred geometry of Breslow intermediates likely depends on the *N*-substituent of the NHC.

Scheme 3. Rationale for the stereochemical outcomes of the reaction with **1a** or **1b** (*ent*-**1b** is depicted for clarity).

The above speculation led us to envision that changing the protective groups alters the stereochemistry in the cyclization (Scheme 4). If the 3- and 4-hydroxy groups are protected as an acetonide as shown in **11**, the reaction should proceed via chair conformation **B** or **C**. In **B**, there are one repulsive 1,3-diaxial interaction and one non-minimum A^{1,3} strain, while **C** has two repulsive 1,3-diaxial interactions and an unfavorable bisect allylic conformation. If **B** is more stable than **C**, then inosose **12** with a hydroxy group in the *S*-configuration should be produced.

Scheme 4. Transition states **B** and **C** leading to **12** and *epi*-**12**, respectively.

Thus, the reaction was performed with dialdose **11a**, which has TIPSO groups at the 2- and 5-positions with acetonide as a protective group for the 3- and 4-hydroxy groups. As expected, with **9c** as an NHC precursor, **12a** was formed preferentially over

epi-**12a** (74:26), and **12a** and *epi*-**12a** were produced in 53% combined yield (Table 2, entry 3). With **10** or *ent*-**10**, the reaction was much slower, giving an almost 1:1 mixture of **12a** and *epi*-**12a** in 13 and 7% combined yield, respectively (entries 1 and 2). This is probably because the bulky NHCs enforce the A^{1,3} strain in transition state **B** as well as the 1,3-diaxial interaction in **C** (Scheme 4).

Table 2. Reactions of **11a–c** protected with acetonide.

entry	11	NHC·HX	12	yield/% ^a	12 : <i>epi</i> - 12 ^b
1	11a	10	12a	13 (61)	48:52
2	11a	<i>ent</i> - 10	12a	7 (47)	49:51
3	11a	9c	12a	53 (31)	74:26
4	11b	9c	12b	30 (3)	57:43
5	11c	9c	12c	49 (29)	>99:1
6	11c	9c	12c	55 ^d (4)	>99:1

^a Combined yield of **12** and *epi*-**12** determined by ¹H NMR with Ph₃CH as an internal standard. Number in parentheses is the recovery yield of **11**. ^b Determined by ¹H NMR of the crude mixture. ^c 20 mol %. ^d Isolation yield.

The axially oriented substituents at the 2,5-positions significantly influence the selectivity. The product ratio was reduced to 57:43 in the reaction with **11b**, which has less bulky benzyloxy groups (entry 4), while **12c** was produced with perfect selectivity (>99:1) when the reaction was conducted using **11c**, which bears more bulky TBDPSO groups (entry 5). This observation indicates that the two 1,3-diaxial repulsions in **C** are predominant over the A^{1,3} strain in **B** (Scheme 4). Finally, using 20 mol % of **9c**, **12c** was obtained in 55% yield as a single diastereomer (entry 6). The stereochemistry of **12c** was determined by the NOE experiment (Figure 2).

Stereoselective reduction of inososes to give inositol

To selectively obtain *allo*- and *chiro*-inositols from **2a**, the conditions for stereoselective reduction were investigated (Table 3). Treating **2a** with NaBH₄ in methanol gave *allo*-inositol derivative *allo*-**3a** in 81% yield as a single diastereomer (entry 1). The stereochemistry was determined by X-ray crystallography. Thus, conditions to produce *chiro*-**3a** were examined. Although neither reduction using NaBH(OAc)₃ nor BH₃·THF produced *chiro*-**3a**, reduction with BH₃·SMe₂ gave *chiro*-**3a** as a minor diastereomer (entry 2). The proportion of *chiro*-**3a** in the product increased to 30% and 56% when BH₃·NH₃ and *t*-BuNH₂·BH₃^[32] were used as a hydride source, respectively (entries 3 and 4).

Table 3. Selectivity in the reduction of **2a** and **2c–f**.^a

2a: R = H
2c: R = TBDPS
2e: R = TES
2d: R = TBDMS
2f: R = TMS

entry	2	H [−] source	solvent	yield	dr
1	2a	NaBH ₄	MeOH	81% ^b	>99:1
2	2a	BH ₃ ·SMe ₂	THF	quant	92:8
3	2a	BH ₃ ·NH ₃	THF	96%	70:30
4	2a	<i>t</i> -BuNH ₂ ·BH ₃	THF	98%	44:56
5	2c	<i>t</i> -BuNH ₂ ·BH ₃	toluene	93% ^b	33:67
6	2d	<i>t</i> -BuNH ₂ ·BH ₃	toluene	96%	19:81
7	2e	<i>t</i> -BuNH ₂ ·BH ₃	toluene	87% ^c	10:90
8	2f	<i>t</i> -BuNH ₂ ·BH ₃	toluene	88%	16:84

^a Yield and dr (ratio of *allo*- and *chiro*-**3a**) were determined by ¹H NMR using Ph₃CH as an internal standard unless otherwise noted. ^b Isolated yield. ^c Isolated yield over two steps from **2a**.

The observed selectivity can be explained as follows. Hydride reduction of inososes generally occurs from the less hindered side,^[51] due to the electron-negative substituents of inosose, which enhances the electrophilicity of the carbonyl group and induces an early transition state. Consequently, steric hindrance becomes a controlling factor. When an amine–borane complex is used as a hydride source, its relatively low reducing ability causes a later transition state. Consequently, torsional strain becomes more important (Figure 3).

Figure 3. Rationale for stereoselectivity in Table 3.

Based on the above speculation, the α -hydroxy group of **2a** was protected with a bulky silyl group to increase the torsional strain. As expected, the selectivity was further improved to 67–90% (entries 5–8). The TES group gave the best result, and *chiro*-**3a** was obtained with a high diastereoselectivity (90:10) in 87% yield after treatment with TBAF (entry 7). The two epimers were easily separated by silica gel column chromatography.

A similar selectivity was observed in the reduction of **2b** (Scheme 5). Reduction by NaBH₄ occurred preferentially from the equatorial direction to give *myo*-**3b** with a slightly lower selectivity (98:2) than that of **2a**, probably due to the reduced steric hindrance of the axial side. The use of L-selectride afforded *myo*-**3b** as a single diastereomer. Protection

with a TES group and reduction using *t*-BuNH₂·BH₃ exclusively produced *scyllo*-**3b** after protodesilylation.

Scheme 5. Stereoselective reduction of **2b**.

With **12c**, BH₃·THF was used for the reduction from the equatorial direction to give an *allo*-rich mixture (89:11) of **13c** in 93% yield (Scheme 6). In contrast, NaBH₄ gave the opposite selectivity, and reduction from the axial direction was slightly preferred to give a 75:25 mixture of *neo*- and *allo*-**13c**. This preference is attributable to the steric hindrance by the axial TBDPSO group at the α -position. Reduction with *t*-BuNH₂·BH₃ after TES protection gave *neo*-**13c** with a high diastereoselectivity (*neo*:*allo* = 96:4).

Scheme 6. Stereoselective reduction of **12c**.

Synthesis of other cyclitol derivatives and deprotection

To show the utility of the inososes **2** as synthetic intermediates, several transformations of **2a** were demonstrated (Scheme 7). Amino sugar **4a** was obtained along with minor diastereomer *epi*-**4a** by LiAlH₄/NaOMe reduction of the *O*-methyl oxime^[33] derived from **2a**. The stereoselectivity of the reduction was reversed when the *O*-acetyl oxime was reduced with NaBH₄/NiCl₂,^[34] and *epi*-**14a** was obtained as a sole diastereomer after acetylation. Deoxygenation of **2a** via thiocarbonate and subsequent reduction of the carbonyl group afforded deoxyinositol, *talo*-quercitol derivative **5a**. The stereochemistries of **4a**, *epi*-**4a**, and **5a** were determined after acetylation on the basis of the coupling constants (**14a**, *epi*-**14a**, and **15a**).

Scheme 7. Conversion of **2a** into other derivatives.

Treatment of **2a** with the Meerwein reagent and subsequent reduction gave *O*-methylinositol, *epi*-D-pinitol derivative **6a**. Reaction of **2a** with methylolithium provided *C*-methylinositol **7a** as the sole diastereomer. The stereochemistry of **6a** was confirmed by the coupling constants, while that of **7a** was determined by NOESY after conversion into acetone **16a**.

As reported with *allo*-**3a**,^[24] the benzyl groups were easily removed. Hydrogenolysis of **2a** and *chiro*-**3a** using Pd/C under a hydrogen atmosphere gave *allo*-2-inosose and *D*-*chiro*-inositol in 84% and 81% yields, respectively (Scheme 8). Deprotection of acetone *neo*-**13c** was reported in the literature.^[12c] By analogy, the other compounds should be deprotected in similar manners.

Scheme 8. Deprotection of the products.

Conclusion

We have developed a divergent method to synthesize cyclitol derivatives utilizing NHC-catalyzed benzoin-type cyclization of C_2 -symmetric dialdose. With tetrabenzyl-protected dialdose, the key for efficient cyclization is the chiral triazolyldene catalyst. Acetonide protection at the 3,4-positions inverts the selectivity in the cyclization of the mannitol-derived dialdose. In the stereoselective reduction, employing *t*- $\text{BuNH}_2\cdot\text{BH}_3$ as a hydride source with the α -*O*-TES protection of inosose is highly effective to overcome the inherent preference for reduction from the axial direction. The inosose products are versatile intermediates, which can be converted into various cyclitol derivatives. These results testify to the validity of our strategy in Scheme 1. Future investigations include broadening the scope of the methodology to non- C_2 -symmetric dialdoses.

Experimental Section

General. All melting points are uncorrected. NMR (500 and 125 MHz for ^1H and ^{13}C , respectively) was measured in CDCl_3 unless otherwise mentioned. Chemical shifts (δ) and coupling constants (J) are presented in parts per million relative to tetramethylsilane and hertz, respectively. Abbreviations are as follows: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad. ^{13}C peak multiplicity assignments were made based on DEPT. The wave numbers of maximum absorption peaks of IR spectroscopy are presented in cm^{-1} . Quadrupole, double-focusing magnetic sector, and TOF mass spectrometers were used for EI-, FAB-, and ESI-MS, respectively. Silica gel was used for column chromatography. Reactions were conducted under argon atmosphere unless otherwise noted.

Materials. Triazoliums **9c**, **10**, and *ent*-**10** were prepared as reported.^[35] $(\text{COCl})_2$, Et_3N , 2,6-lutidine, TMSCl , and CH_2Cl_2 were purchased and distilled prior to use. Other starting materials, reagents and solvents were purchased and used as supplied unless a literature for the preparation is cited. Commercially available anhydrous solvents were used as reaction solvents, except for MeOH and CH_2Cl_2 . DMSO and pyridine utilized in reactions were anhydrous grade.

Table 1. 2,3,4,5-Tetra-*O*-benzyl-D-manno-hexodialdose (1a): A solution of $(\text{COCl})_2$ (0.25 mL, 2.9 mmol) in CH_2Cl_2 (1.5 mL + 0.5 mL wash) was added to a solution of DMSO (0.21 mL, 2.9 mmol) in CH_2Cl_2 (4.5 mL) cooled at -78°C . After 2 min, a solution of 2,3,4,5-tetra-*O*-benzyl-D-mannitol^[36] (621 mg, 1.14 mmol) in CH_2Cl_2 (3 mL + 1 mL wash $\times$ 2) was added over 5 min. After 1.5 h, Et_3N (1.6 mL, 11 mmol) was added, and the mixture was stirred for additional 10 min before the cooling bath was removed. The mixture was allowed to warm to rt and concentrated *in vacuo*. The resulting white solids was suspended in a 1:1 mixture of pentane and EtOAc (20 mL), filtered, and washed with the mixed solvent (20 mL $\times$ 2). The combined filtrate was concentrated *in vacuo* to give a 58:28:14 mixture of the title compound, EtOAc, and DMSO as a pale yellow oil (682 mg, quant): IR (neat): 3441, 3062, 3031, 2861, 1728, 1496, 1458, 1373, 1258, 1211, 1096, 910, 741, 702, 602, 455, 463. ^1H NMR: 4.05 (br s, 2H), 4.12 (br s, 2H), 4.43 (d, $J = 12.0$, 2H), 4.51 (d, $J = 11.0$, 2H), 4.60 (d, $J = 11.0$, 2H), 4.65 (d, $J = 12.0$, 2H), 7.20–7.36 (m, 20H) 9.70 (d, $J = 1.5$, 2H). ^{13}C NMR: 72.5 (CH_2), 73.7 (CH_2), 80.0 (CH), 83.2 (CH), 127.9 (CH), 127.97 (CH), 128.00 (CH), 128.1 (CH $\times$ 2), 128.3 (CH), 128.4 (CH), 136.9 (C), 137.1 (C), 201.0 (C). FABMS m/z : 561

(M + Na). This oil was used for the next reaction without further purification.

(2S,3S,4R,5R,6R)-2,3,4,5-Tetrakis(benzyloxy)-6-hydroxycyclohexanone (2a) (entry 10): EtOAc was removed from the above mixture of **1a** (174 mg, 0.290 mmol) by evaporation with toluene (5 mL × 3), and the residue was dissolved in toluene (3 mL). To a suspension of triazolium salt **10** (6.8 mg, 0.015 mmol) in toluene (5.5 mL), a 1% v/v solution of Et₃N in toluene (0.20 mL, 0.015 mmol) was added, and after 30 min, the above solution of **1a** was added (1.5 mL toluene wash × 2). After 45 min, the mixture was concentrated *in vacuo*, and the residue was purified by column chromatography (toluene/EtOAc 40/1 to 20/1) to give the title compound (138 mg, 88%) as a colorless oil with $[\alpha]_D^{25} -65.1$ (c 1.00, CHCl₃): IR (neat): 3472, 3032, 2924, 2878, 1736, 1636, 1497, 1458, 1366, 1327, 1211, 1111, 910, 741, 702, 463. ¹H NMR (C₆D₆): 3.76 (br s, 1H), 3.86 (dd, *J* = 3.5, 4.0, 1H), 3.96 (dd, *J* = 3.0, 9.5, 1H), 4.02 (t, *J* = 4.0, 1H), 4.05 (d, *J* = 9.5, 1H), 4.37 (d, *J* = 12.0, 1H), 4.43 (d, *J* = 12.0, 1H), 4.50 (d, *J* = 12.0, 1H), 4.55 (dd, *J* = 1.5, 3.0, 1H), 4.76 (br d, *J* = 12.0, 3H), 4.81 (d, *J* = 11.5, 1H), 4.95 (d, *J* = 12.0, 1H), 7.31–7.34 (m, 4H), 7.27–7.35 (m, 16H). ¹³C NMR: 72.6 (CH₂), 73.4 (CH₂), 73.5 (CH₂), 73.7 (CH₂), 75.0 (CH), 76.5 (CH), 77.7 (CH), 80.3 (CH), 82.3 (CH), 127.6 (CH), 127.72 (CH × 2), 127.74 (CH), 127.8 (CH), 127.9 (CH × 2), 128.29 (CH × 2), 128.32 (CH), 128.35 (CH), 128.40 (CH), 137.5 (C), 137.7 (C), 137.8 (C), 138.3 (C), 205.1 (C). EIMS *m/z*: 538 (M⁺). HRMS–FAB (*m/z*): [M + Na]⁺ calcd for C₃₄H₃₄NaO₆, 561.2253; found, 561.2249. The stereochemistry was determined based on the *trans*-diaxial coupling (*J* = 9.5 Hz) between 5-H and 6-H (3.96 and 4.05 ppm, respectively) as shown in Figure 2.

(2S,3S,4R,5R,6R)-2,3,4,5-Tetrakis(benzyloxy)-6-hydroxycyclohexanone (2a) (entry 11): To a solution of DMSO (2.2 mL, 31 mmol) in CH₂Cl₂ (60 mL) cooled at –78 °C, a solution of (COCl)₂ (2.5 mL, 29 mmol) in CH₂Cl₂ (20 mL) was added over 20 min. After 2 min, a solution of 2,3,4,5-tetra-*O*-benzyl-D-mannitol (6.0 g, 11 mmol) in CH₂Cl₂ (20 mL + 10 mL wash) was added over 30 min. After 1.5 h, Et₃N (10 mL, 72 mmol) was added, and the mixture was stirred for additional 15 min before the cooling bath was removed. The mixture was allowed to warm to rt and evaporated. The resulting white solids were suspended in a 1:1 mixture of pentane and EtOAc (20 mL), filtered, and washed with the mixed solvent (5 mL × 2). The combined filtrate was concentrated *in vacuo* to give a mixture of **1a** and DMSO as orange oil. The oil was dissolved in toluene (240 mL) and added to a premixed suspension of triazolium salt **10** (240 mg, 0.51 mmol) and Et₃N (80 μL, 0.58 mmol) in toluene (200 mL). After 1 h, the mixture was evaporated, and the residue was purified by column chromatography (hexane/EtOAc 3/1) to give the title compound (5.4 g, 90%) as a pale yellow oil.

Scheme 2. 2,3,4,5-Tetra-*O*-benzyl-L-ido-hexodialdose (1b): The same procedure as **1a** using 2,3,4,5-tetra-*O*-benzyl-L-iditol^[37] (331 mg, 0.611 mmol) in place of 2,3,4,5-tetra-*O*-benzyl-D-mannitol gave a 71:29 mixture of the title compound, and DMSO as yellow oil (349 mg, quant). ¹H and ¹³C NMR were identical to those reported.^[38] This oil was used for the next reaction, without further purification.

(2R,3S,4R,5S,6S)-2,3,4,5-Tetrakis(benzyloxy)-6-hydroxycyclohexanone (2b): To a suspension of triazolium salt *ent*-**10** (14 mg, 0.030 mmol) in toluene (6 mL), a 10% v/v solution of Et₃N in toluene (0.04 mL, 0.03 mmol) was added at rt. After 30 min, **1b**^[38] (160 mg, 0.290 mmol) in toluene (3 mL + 1.5 mL wash × 2) was added. After 18 h, the mixture was concentrated *in vacuo*. The residue was purified by column chromatography (toluene/EtOAc 19/1) to give the title compound (137 mg, 86%) as a white solid of mp 159–161 °C (decomp) with $[\alpha]_D^{25} +24.4$ (c 1.00, CHCl₃): IR (KBr): 3435, 1730. ¹H NMR: 3.42 (t, *J* = 9.5, 1H), 3.47 (d, *J* = 4.5, 1H), 3.65 (t, *J* = 9.5, 1H), 3.89 (t, *J* = 9.5, 1H), 4.30 (dd, *J* = 2.0, 9.5, 1H),

4.37 (ddd, *J* = 2.0, 4.5, 9.5, 1H), 4.58 (d, *J* = 11.5, 1H), 4.790 (d, *J* = 11.0, 1H), 4.794 (d, *J* = 11.0, 1H), 4.86–4.91 (m, 3H), 4.91 (d, *J* = 11.5, 1H), 4.96 (d, *J* = 11.0, 1H), 7.20–7.40 (m, 20H). ¹³C NMR: 73.5 (CH₂), 75.4 (CH₂), 76.1 (CH₂ × 2), 77.3 (CH), 81.4 (CH), 81.7 (CH), 83.2 (CH), 83.6 (CH), 127.7 (CH), 127.78 (CH), 127.80 (CH), 127.9 (CH), 128.0 (CH), 128.09 (CH), 128.13 (CH), 128.4 (CH), 128.5 (CH), 137.0 (C), 137.9 (C), 138.0 (C), 138.1 (C), 204.1 (C). IR, and ¹H and ¹³C NMR were in good agreement with those reported.^[39]

Table 2. 3,4-*O*-Isopropylidene-2,5-bis-*O*-triethylsilyl-D-manno-hexodialdose (11a): To a solution of DMSO (0.19 mL, 2.3 mmol) in CH₂Cl₂ (4 mL) cooled at –78 °C, a solution of (COCl)₂ (0.21 mL, 2.5 mmol) in CH₂Cl₂ (2 mL + 1 mL wash) was added. The resulting mixture was stirred for 2 min before a solution of 3,4-*O*-isopropylidene-2,5-bis-*O*-triisopropylsilyl-D-mannitol^[12c] (535 mg, 1.00 mmol) in CH₂Cl₂ (3 mL + 0.5 mL wash × 2) was added over 5 min. After 1.5 h, Et₃N (1.4 mL, 10 mmol) was added, and the mixture was stirred for additional 10 min. After addition of pentane (20 mL), the cooling bath was removed, and the mixture was allowed to warm to rt. The resulting suspension was filtered, and the filtered solids were washed with a 1:1 mixture of pentane and EtOAc (20 mL × 2). The volume of combined filtrate was reduced to ca 10 mL by evaporation, and the resulting suspension was further diluted with pentane (10 mL). The whole was filtered, and the filtered solids were washed with the mixed solvent (10 mL × 2). The combined filtrate was concentrated *in vacuo* to give a 63:30:6 mixture of the title compound, EtOAc, and DMSO as a yellow oil (570 mg, 98%): IR (neat): 1943, 2866, 1736, 1466, 1381, 1238, 1219, 1153, 1107, 1072, 1045, 1015, 999, 883, 760. ¹H NMR: 1.00–1.20 (m, 42H), 1.35 (s, 6H), 4.21 (br s, 2H), 4.42 (br s, 2H), 9.68 (d, *J* = 1.5, 1H). ¹³C NMR: 12.2 (CH), 17.8 (CH₃), 26.9 (CH₃), 76.9 (CH), 77.8 (CH), 109.8 (C), 202.7 (CH). HRMS–ESI *m/z*: [M + Na]⁺ calcd for C₂₇H₅₄NaO₆Si₂, 553.3351; found, 553.3352. This oil was used for the next reaction without further purification.

2,5-Di-*O*-Benzyl-3,4-*O*-isopropylidene-D-manno-hexodialdose (11b):^[12c] To a solution of (COCl)₂ (0.26 mL, 3.0 mmol) in THF (3.5 mL) cooled at –19 °C, was added a 1 M solution of DMSO in THF (3.1 mL, 3.1 mmol) at such a rate that the temperature did not rise above –18 °C. After 2 min, the mixture was cooled at –78 °C and stirred for additional 10 min. A solution of 2,5-di-*O*-benzyl-3,4-*O*-isopropylidene-D-mannitol^[12c] (402 mg, 1.00 mmol) in CH₂Cl₂ (7 mL + 1 mL wash) was added over 5 min. After 30 min, Et₃N (1.4 mL, 10 mmol) was added. After 10 min, the cooling bath was removed, and the mixture was allowed to warm to rt. After addition of pentane (10 mL), the resulting suspension was filtered, and the filtered solids were washed with a 1:1 mixture of pentane and EtOAc (15 mL × 2). The volume of the combined filtrate was reduced by evaporation to ca 10 mL, and the resulting suspension was further diluted with pentane (5 mL) and filtered. The filtered solids were washed with the mixed solvent (15 mL × 2). Concentration of the filtrate gave a 39:31:30 mixture of the title compound, DMSO, and EtOAc as a yellow oil (510 mg, 97%): ¹H NMR: 1.36 (s, 6H), 3.87 (dd, *J* = 2.0, 3.0, 1H), 3.88 (dd, *J* = 2.0, 3.0, 1H), 4.33 (d, *J* = 3.0, 1H), 4.34 (d, *J* = 3.0, 1H), 4.57 (d, *J* = 12.0, 2H), 4.64 (d, *J* = 12.0, 2H), 7.27–7.37 (m, 10H), 9.58 (d, *J* = 2.0, 2H). ¹³C NMR: 201.4 (C), 136.4 (CH), 128.6 (CH), 128.4 (CH), 110.8 (C), 83.0 (CH), 77.4 (CH), 73.3 (CH₂), 26.6 (CH₃). IR (neat): 3256, 3090, 3063, 3032, 2986, 2932, 2874, 2723, 1736, 1454, 1381, 1138, 1084, 1026, 914, 868, 810, 748. HRMS–ESI *m/z*: [M + Na]⁺ calcd for C₂₃H₂₆O₆Na, 421.1622; found, 421.1625. This oil was used for the next reaction without further purification.

2,5-Bis-*O*-tert-butylidiphenylsilyl-3,4-*O*-isopropylidene-D-manno-hexodialdose (11c):^[12c] The same procedure as **11a** using 3,4-*O*-isopropylidene-2,5-bis-*O*-tert-butylidiphenylsilyl-D-mannitol^[12c] (1.02 g, 1.46 mmol) in place of 3,4-*O*-isopropylidene-2,5-bis-*O*-triisopropylsilyl-D-mannitol gave a 52:37:11 mixture of the title compound,

EtOAc, and DMSO as a pale yellow oil (1.11 g, 98%): IR (neat): 3071, 3051, 2959, 2932, 2859, 1740, 1474, 1427, 1381, 1234, 1111, 1076, 9999, 822, 760, 741. ^1H NMR: 1.07 (s, 18H), 1.30 (s, 6H), 3.75 (br s, 2H), 4.27 (br s, 2H), 7.25–7.39 (m, 12H), 7.54–7.60 (m, 8H), 9.25 (s, 2H). ^{13}C NMR: 14.2 (C), 26.8 (CH₃), 76.1 (CH), 78.5 (CH), 110.1 (C), 127.8 (CH), 127.9 (CH), 130.0 (CH), 130.2 (CH), 132.27 (C), 132.28 (C), 135.75 (CH), 135.77 (CH), 202.0 (CH). HRMS–ESI m/z : $[\text{M} + \text{Na}]^+$ calcd for C₄₁H₅₀NaO₆Si₂, 717.3038; found, 717.3028. The oil was used for the next reaction without further purification.

(2S,3S,4R,5R,6S)- and (2S,3S,4R,5R,6R)-3,4-isopropylidenedioxy-2,5-bis(triisopropylsiloxy)-6-hydroxycyclohexanone (12a and *epi*-12a) (entry 3): EtOAc was removed from the above mixture of **11a** (212 mg, 0.365 mmol) by evaporation with toluene (5 mL $\times$ 3), and the residue was dissolved in toluene (6.5 mL). To a suspension of triazolium salt **9c** (13 mg, 0.037 mmol) in toluene (7 mL), a 1% v/v solution of Et₃N in toluene (0.51 mL, 0.037 mmol) was added, and after 30 min, the above solution of **11a** was added (2 mL toluene wash). After 24 h, the mixture was concentrated *in vacuo* to give a crude product. The yield (53%) and diastereomeric ratio (74:26) of the title compounds, and the recovery yield of **11a** (31%) were determined by integration area of ^1H NMR signals at 4.75 (**12a**), 4.13 (*epi*-**12a**), and 9.67 (**11a**) ppm with Ph₃CH (5.55 ppm) as an internal standard. The diastereomers were separated by column chromatography (toluene/hexane 5:1) to give **12a** as a pale yellow solid of mp 48–50 °C with $[\alpha]_D^{25} +6.2$ (c 1.0, CHCl₃) and *epi*-**12a** as a pale yellow oil, containing ca 10% unidentified impurity. The stereochemistry was tentatively assigned by analogy with that of **12c**.

12a: IR (KBr): 3510, 2943, 2866, 1736, 1466, 1381, 1369, 1227, 1165, 1138, 1069, 1049, 1018, 883, 864, 849, 822, 799. ^1H NMR: 1.00–1.20 (m, 42H), 1.44 (s, 3H), 1.46 (s, 3H), 3.17 (br d, $J = 7.0$, 1H), 3.98 (dd, $J = 2.5$, 9.5, 1H), 4.45 (dd, $J = 2.0$, 9.5, 1H), 4.65 (d, $J = 2.5$, 1H), 4.67 (dd, $J = 3.0$, 7.0, 1H), 4.75 (dd, $J = 2.0$, 3.0, 1H). ^{13}C NMR: 11.9 (CH₃), 12.6 (CH₃), 17.6 (CH₃), 17.7 (CH₃), 17.9 (CH₃), 18.0 (CH₃), 26.8 (CH₃), 27.1 (CH₃), 70.2 (CH), 73.7 (CH), 73.8 (CH), 74.2 (CH), 75.4 (CH), 112.5 (C), 207.2 (C). HRMS–ESI m/z : $[\text{M} + \text{Na}]^+$ calcd for C₂₇H₅₄NaO₆Si₂, 553.3351; found, 553.3351.

***epi*-12a:** IR (neat): 3507, 2943, 2870, 1736, 1466, 1381, 1227, 1134, 1057, 1042, 1015, 883, 853, 826, 760. ^1H NMR: 1.00–1.20 (m, 42H), 1.44 (s, 3H), 1.47 (s, 3H), 3.68 (d, $J = 8.5$, 1H), 4.00 (ddd, $J = 1.0$, 3.0, 8.5, 1H), 4.13 (dd, $J = 3.0$, 10.0, 1H), 4.45 (d, $J = 3.0$, 10.0, 1H), 4.49 (t, $J = 3.0$, 1H), 4.66 (dd, $J = 1.0$, 3.0, 1H). ^{13}C NMR: 12.0 (CH₃), 12.2 (CH₃), 17.5 (CH₃), 17.65 (CH₃), 17.68 (CH₃), 17.8 (CH₃), 26.9 (CH₃), 27.1 (CH₃), 70.6 (CH), 73.3 (CH), 74.3 (CH), 77.5 (CH), 80.5 (CH), 112.1 (C), 203.7 (C). HRMS–ESI m/z : $[\text{M} + \text{Na}]^+$ calcd for C₂₇H₅₄NaO₆Si₂, 553.3351; found, 553.3351.

(2S,3S,4R,5R,6S)- and (2S,3S,4R,5R,6R)-2,5-Bis(benzyloxy)-3,4-isopropylidenedioxy-6-hydroxycyclohexanone (12b and *epi*-12b) (entry 4): EtOAc was removed from the above mixture of **11b** (148 mg, 0.280 mmol) by evaporation with toluene (5 mL $\times$ 3), and the residue was dissolved in toluene (3.5 mL). To a suspension of triazolium salt **9c** (10 mg, 0.028 mmol) in toluene (5 mL), a 1% v/v solution of Et₃N in toluene (0.39 μL , 0.028 mmol) was added, and after 30 min, the above solution of **11b** was added (1 mL toluene wash). After 24 h, the mixture was concentrated *in vacuo* to give a crude product. The yield (30%) and diastereomeric ratio (57:43) of the title compounds, and the recovery yield of **11b** (3%) were determined by integration area of ^1H NMR signals at 4.14 (**12b**), 4.26–4.33 (*epi*-**12b**, 2H), and 9.58 (**11b**) ppm with Ph₃CH (5.55 ppm) as an internal standard. The diastereomers were separated by column chromatography (hexane/EtOAc 8/1 to 4/1). The stereochemistry was tentatively assigned by analogy with that of **12c**.

12b: a colorless oil with $[\alpha]_D^{20} -4.8$ (c 1.4, CHCl₃). IR (neat): 3464, 3090, 3063, 3032, 2986, 2932, 2874, 1736, 1497, 1454, 1381, 1346, 1231, 1169, 1126, 1069, 1057, 1026, 972, 910, 849, 802, 741. ^1H NMR: 1.49 (s, 3H), 1.54 (s, 3H), 3.12 (br s, 1H), 4.14 (dd, $J = 2.5$, 10.0, 1H), 4.38 (d, $J = 2.5$, 1H), 4.41 (dd, $J = 2.0$, 4.0, 1H), 4.55 (dd, $J = 2.0$, 10.0, 1H), 4.57 (d, $J = 11.5$, 1H), 4.60 (br d, $J = 4.0$, 1H), 4.69 (d, $J = 12.5$, 1H), 4.72 (d, $J = 12.5$, 1H), 4.87 (d, $J = 11.5$, 1H), 7.27–7.38 (m, 10H). ^{13}C NMR (C₆D₆): 26.8 (CH₃), 26.9 (CH₃), 73.0 (CH₂), 74.1 (CH), 74.50 (CH₂), 74.54 (CH), 75.5 (CH), 75.6 (CH), 80.0 (CH), 112.4 (C), 127.76 (CH), 127.78 (CH), 127.9 (CH), 128.52 (CH), 128.53 (CH), 128.6 (CH), 137.5 (C), 138.7 (C), 205.7 (C). HRMS–ESI m/z : $[\text{M} + \text{Na}]^+$ calcd for C₂₃H₂₆O₆Na, 421.1622; found, 421.1622.

***epi*-12b:** a white solid of mp 121–124 °C with $[\alpha]_D^{20} +11.5$ (c 1.82, CHCl₃). IR (neat): 3329, 3090, 3063, 3028, 2982, 2932, 2909, 2882, 1744, 1497, 1454, 1396, 1381, 1242, 1219, 1180, 1150, 1123, 1096, 1049, 1022, 968, 914, 976, 845, 795, 752, 733. ^1H NMR: 1.50 (s, 3H), 1.52 (s, 3H), 3.40 (br d, $J = 6.5$, 1H), 3.97 (dt, $J = 8.0$, 1.5, 1H), 4.20 (br m, 1H), 4.26–4.33 (m, 2H), 4.40 (dd, $J = 1.5$, 4.0, 1H), 4.73 (d, $J = 11.5$, 1H), 4.74 (d, $J = 11.5$, 1H), 4.86 (d, $J = 11.5$, 1H), 4.88 (d, $J = 11.5$, 1H), 7.27–7.37 (m, 8H), 7.43 (d, $J = 7.5$, 2H). ^{13}C NMR (C₆D₆): 26.5 (CH₃), 27.2 (CH₃), 72.3 (CH₂), 74.3 (CH₂), 74.8 (CH), 75.7 (CH), 76.8 (CH), 77.0 (CH), 81.8 (CH), 112.6 (C), 127.68 (CH), 127.74 (CH), 127.9 (CH), 128.0 (CH), 128.5 (CH), 128.6 (CH), 138.3 (C), 138.5 (C), 205.2 (C). HRMS–ESI m/z : $[\text{M} + \text{Na}]^+$ calcd for C₂₃H₂₆O₆Na, 421.1622; found, 421.1622.

(2S,3S,4R,5R,6S)-2,5-Bis(*tert*-butyldiphenylsiloxy)-3,4-isopropylidenedioxy-6-hydroxycyclohexanone (12c) (entry 6): EtOAc was removed from the above mixture of **11c** (367 mg, 0.474 mmol) by evaporation with toluene (5 mL $\times$ 2), and the residue was dissolved in toluene (7.5 mL). To a suspension of triazolium salt **9c** (34 mg, 0.095 mmol) in toluene (9.5 mL), a 10% v/v solution of Et₃N in toluene (0.13 mL, 0.095 mmol) was added, and after 30 min, the above solution of **11c** was added (1 mL toluene wash $\times$ 2). After 24 h, the mixture was concentrated *in vacuo* to give a crude product (469 mg) as a yellow oil. The yield was estimated to be 57% by integration area of ^1H NMR signals at 4.57–4.66 (4H) with Ph₃CH (5.55 ppm) as an internal standard. The above oil was purified by column chromatography (DIOL silica gel, hexane to hexane/EtOAc 98:2) to give **12c** (181 mg, 55%) as a white solid of mp 156–157 °C with $[\alpha]_D^{25} +12.6$ (c 3.03, CHCl₃): IR (neat): 3510, 3071, 3051, 2954, 2932, 2893, 2859, 1732, 1589, 1470, 1427, 1369, 1227, 1169, 1130, 1111, 1068, 1049, 968, 937, 864, 821, 799, 753, 741, 702. ^1H NMR: 1.02 (s, 9H), 1.04 (s, 9H), 1.46 (s, 3H), 1.51 (s, 3H), 2.72 (d, $J = 7.5$, 1H), 4.12 (dd, $J = 8.5$, 10.0, 1H), 4.59 (dd, $J = 1.5$, 10.0, 1H), 4.62–4.65 (m, 2H), 4.66 (d, $J = 2.5$, 1H), 7.30–7.46 (m, 12H), 7.50 (m, 2H), 7.53 (m, 2H), 7.70 (m, 2H), 7.77 (m, 2H). ^{13}C NMR (C₆D₆): 1.09 (s, 9H), 1.18 (s, 9H), 1.41 (s, 3H), 1.45 (s, 3H), 3.02 (d, $J = 7.0$, 1H), 4.08 (dd, $J = 2.5$, 10.0, 1H), 4.34 (dd, $J = 1.0$, 10.0, 1H), 4.67 (d, $J = 3.5$, 7.0, 1H), 4.60 (dd, $J = 1.0$, 3.5, 1H), 4.73 (d, $J = 2.5$, 1H), 7.13–7.28 (m, 12H), 7.61–7.69 (m, 4H), 7.77–7.83 (m, 2H), 7.94–7.99 (m, 2H). ^{13}C NMR: 19.3 (C), 19.6 (C), 26.75 (CH₃), 26.85 (CH₃), 26.89 (CH₃), 27.1 (CH₃), 70.8 (CH), 73.6 (CH), 73.9 (CH), 74.6 (CH), 75.7 (CH), 127.48 (CH), 127.52 (CH), 127.68 (CH), 127.79 (CH), 129.54 (CH), 129.88 (CH), 130.01 (CH), 130.2 (CH), 131.86 (C), 132.00 (C), 132.1 (C), 134.1 (C), 135.7 (CH), 135.9 (CH), 136.7 (CH), 206.1 (C). HRMS–FAB m/z : $[\text{M} + \text{Na}]^+$ calcd for C₄₁H₅₀O₆Si₂Na, 717.3038; found, 717.3033. The relative configuration was determined by 2% nOe between 4-H and 6-H (4.34 and 4.67 ppm in C₆D₆, respectively) as shown in Figure 2.

Table 3. (2S,3S,4S,5S,6R)-2,3,4,5-Tetrakis(benzyloxy)-6-(*tert*-butyldiphenylsiloxy)cyclohexanone (2c). To a solution of **2a** (108 mg, 0.201 mmol), imidazole (27 mg, 0.40 mmol), and DMAP (5 mg, 0.4 mmol), in DMF (0.4 mL) was added TBDPSCI (0.06 mL, 0.2 mmol) at rt. After 8.5 h, TBDPSCI (0.04 mL, 0.2 mmol) was added. After 2.5

h, water (1 mL) was added, and the whole was extracted with toluene (8 mL $\times$ 3). The combined organic layers were washed three times with water and with brine, dried over Na_2SO_4 , and evaporated under reduced pressure. The residue was purified by column chromatography (toluene/hexane 3:1 and then hexane/EtOAc 9:1) to give a colorless oil. The oil was dissolved in EtOAc (2 mL), and washed with sat aq NaHCO_3 (2 mL). The aqueous layer was extracted with EtOAc, and the combined organic layers were dried over Na_2SO_4 and evaporated under reduced pressure to yield the title compound (94 mg, 60%) as a colorless oil with $[\alpha]_D^{25} -58.6$ (c 1.35, CHCl_3): IR (neat): 3067, 3028, 2932, 2859, 1748, 1497, 1454, 1427, 1389, 1362, 1215, 1161, 1111, 1080, 1049, 822, 756. ^1H NMR: 1.18 (s, 9H), 3.74 (dd, $J = 3.0, 4.0$, 1H), 3.79 (dd, $J = 3.0, 4.0$, 1H), 3.84 (d, $J = 12.0$, 1H), 3.91 (dd, $J = 3.0, 10.0$, 1H), 4.08 (d, $J = 3.0$, 1H), 4.37 (d, $J = 12.5$, 1H), 4.43 (d, $J = 11.5$, 1H), 4.45 (d, $J = 11.5$, 1H), 4.56 (d, $J = 11.5$, 1H), 4.67 (d, $J = 12.0$, 1H), 4.69 (d, $J = 12.5$, 1H), 4.74 (d, $J = 10.0$, 1H), 4.79 (d, $J = 11.5$, 1H), 7.04–7.14 (m, 6H), 7.21–7.38 (m, 20H), 7.72–7.75 (m, 5H). ^{13}C NMR: 19.6 (C), 27.2 ($\text{CH}_3 \times 3$), 72.0 (CH_2), 73.3 (CH_2), 73.6 (CH_2), 73.9 (CH_2), 75.3 (CH), 77.6 (CH), 78.0 (CH), 80.5 (CH), 82.2 (CH), 127.21 (CH), 127.53 (CH), 127.57 (CH), 127.59 (CH), 127.6 (CH), 127.72 (CH), 128.0 (CH), 128.2 (CH), 128.3 (CH), 129.3 (CH), 129.4 (CH), 133.8 (C), 134.2 (C), 136.1 (CH), 136.6 (CH), 137.8 (C), 138.0 (C), 138.2 (C), 138.3 (C), 201.9 (C). FABMS m/z : 799 ($M + \text{Na}$), 91 (Bn). HRMS–FAB m/z : $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_{50}\text{H}_{52}\text{O}_6\text{SiNa}$, 799.3426; found, 799.3431.

(2S,3S,4S,5S,6R)-2,3,4,5-Tetrakis(benzyloxy)-6-(tert-butylidimethylsiloxy)cyclohexanone (2d): To a solution of **2a** (106 mg, 0.197 mmol) and imidazole (74 mg, 1.1 mmol) in DMF (1 mL) was added TBDMSCl (50 mg, 0.33 mmol) at rt. After 4 h, TBDMSCl (50 mg, 0.33 mmol) was added, and the mixture was stirred for 11 h. After addition of water (1 mL), the whole was extracted with toluene. The organic layer was washed with water three times and with brine, dried over Na_2SO_4 , and evaporated under reduced pressure. The residue was purified by column chromatography (hexane/EtOAc 15:1) to yield the title compound (118 mg, 92%) as a yellow oil with $[\alpha]_D^{25} -24.1$ (c 1.20, CHCl_3): IR (neat): 3088, 3063, 3030, 2951, 2928, 2857, 1746, 1497, 1454, 1389, 1362, 1254, 1207, 1155, 1101, 1051, 1028, 837, 781, 737. ^1H NMR: 0.05 (s, 3H), 0.17 (s, 3H), 0.96 (s, 9H), 3.70 (dd, $J = 3.0, 4.0$, 1H), 3.83 (dd, $J = 3.0, 9.5$, 1H), 3.85 (dd, $J = 3.0, 4.0$, 1H), 4.37 (d, $J = 12.5$, 1H), 4.40 (d, $J = 12.5$, 1H), 4.42 (dd, $J = 1.0, 3.0$, 1H), 4.47 (d, $J = 12.0$, 1H), 4.51 (d, $J = 12.0$, 1H), 4.56 (d, $J = 1.0, 9.5$, 1H), 4.64 (d, $J = 12.5$, 1H), 4.75 (d, $J = 12.5$, 1H), 4.80 (d, $J = 12.0$, 1H), 4.85 (d, $J = 12.0$, 1H), 7.07–7.15 (m, 4H), 7.23–7.35 (m, 16H). ^{13}C NMR: –5.2 (CH_3), –4.7 (CH_3), 18.6 (C), 25.8 ($\text{CH}_3 \times 3$), 72.4 (CH_2), 73.2 (CH_2), 73.7 (CH_2), 74.0 (CH_2), 75.4 (CH), 77.5 (CH), 78.0 (CH), 80.6 (CH), 81.8 (CH), 127.55 (CH), 127.63 (CH), 127.67 (CH), 127.71 (CH), 127.8 (CH), 127.9 (C), 128.2 (C), 128.27 (CH), 128.33 (CH), 128.34 (CH), 137.9 (C), 138.00 (C), 138.04 (C), 138.5 (C), 203.1 (C). FABMS m/z : 675 ($M + \text{Na}$), 91 (Bn). HRMS–FAB m/z : $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_{40}\text{H}_{48}\text{O}_6\text{SiNa}$, 675.3113; found, 675.3118.

(2S,3S,4S,5S,6R)-2,3,4,5-Tetrakis(benzyloxy)-6-(triethylsiloxy)cyclohexanone (2e): To a solution of **2a** (258 mg, 0.440 mmol) and pyridine (0.14 mL, 1.8 mmol) in CH_2Cl_2 (0.8 mL), was added TESCl (0.20 mL, 0.88 mmol) at –78 °C. After 2 h, sat aq NaHCO_3 (2 mL) was added, and the organic layer was separated. The aqueous layer was extracted with toluene (2 mL $\times$ 5). The combined organic layers were washed with water (10 mL $\times$ 5) and brine (10 mL), dried over Na_2SO_4 , and evaporated under reduced pressure. The residue was purified by column chromatography (hexane/EtOAc 96:4) to yield the title compound (118 mg 86%) as a colorless oil with $[\alpha]_D^{20} -37.2$ (c 0.445, CHCl_3). IR (neat): 3086, 3063, 3032, 2955, 2936, 2913, 2874, 1748, 1454, 1385, 1362, 1238, 1207, 1157, 1111, 1084, 1053, 1026, 914, 814, 737. ^1H NMR: 0.58–0.78 (m, 6H), 0.99 (t, $J = 8.0$, 9H), 3.71 (dd, $J = 3.0, 4.0$, 1H), 3.82 (dd, $J = 3.0, 9.5$, 1H), 3.86 (dd, $J = 3.0, 4.0$,

1H), 4.37 (d, $J = 12.0$, 1H), 4.41 (d, $J = 12.0$, 1H), 4.43 (dd, $J = 1.0, 3.0$, 1H), 4.48 (d, $J = 12.0$, 1H), 4.52 (d, $J = 12.0$, 1H), 4.59 (dd, $J = 1.0, 9.5$, 1H), 4.65 (d, $J = 12.0$, 1H), 4.76 (d, $J = 12.0$, 1H), 4.81 (d, $J = 12.0$, 1H), 4.86 (d, $J = 12.0$, 1H), 7.06–7.16 (m, 4H), 7.23–7.35 (m, 16H). ^{13}C NMR: 4.9 (CH_2), 6.8 (CH_3), 72.4 (CH_2), 73.2 (CH_2), 73.7 (CH_2), 74.0 (CH_2), 75.4 (CH), 77.5 (CH), 77.9 (CH), 80.6 (CH), 81.9 (CH), 127.5 (CH), 127.68 (CH), 127.69 (CH), 127.72 (CH), 127.8 (CH), 128.18 (CH), 128.24 (CH), 128.3 (CH), 137.9 (C), 138.0 (C), 138.1 (C), 138.6 (C), 203.1 (C). FABMS m/z : 675 ($M + \text{Na}$), 91 (Bn). HRMS–ESI m/z : $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_{40}\text{H}_{48}\text{O}_6\text{SiNa}$, 675.3113; found, 675.3118.

(2S,3S,4S,5S,6R)-2,3,4,5-Tetrakis(benzyloxy)-6-(trimethylsiloxy)cyclohexanone (2f): To a solution of **2a** (87 mg, 0.16 mmol) and Et_3N (0.09 mL, 0.6 mmol) in CH_2Cl_2 (0.5 mL) was added TMSCl (0.04 mL, 0.3 mmol) at 0 °C. After 1.5 h, Et_3N (0.05 mL, 0.3 mmol) and TMSCl (0.02 mL, 0.2 mmol) were added. After 1.5 h, sat aq NaHCO_3 (4 mL) was added, and the organic layer was separated. The aqueous layer was extracted with EtOAc (4 mL $\times$ 3). The combined organic layers were washed with water (12 mL) and brine (12 mL), dried over Na_2SO_4 , and evaporated to give a crude product as a pale yellow oil: ^1H NMR: 0.31 (s, 9H), 3.87 (dd, $J = 3.0, 4.0$, 1H), 4.07 (dd, $J = 3.0, 4.0$, 1H), 4.11 (dd, $J = 3.0, 9.5$, 1H), 4.21 (d, $J = 12.0$, 1H), 4.40 (d, $J = 12.0$, 1H), 4.42 (d, $J = 12.0$, 1H), 4.45 (d, $J = 12.0$, 1H), 4.62 (dd, $J = 1.0, 3.0$, 1H), 4.75 (d, $J = 12.0$, 1H), 4.76 (d, $J = 12.0$, 1H), 4.83 (d, $J = 12.0$, 1H), 4.88 (dd, $J = 1.0, 9.5$, 1H), 4.92 (d, $J = 12.0$, 1H), 7.03–7.37 (m, 20H). Remaining EtOAc was removed by evaporation with toluene (5 mL). The resulting pale yellow oil was used in the reduction without purification.

(1R,2S,3R,4R,5R,6R)-3,4,5,6-Tetrakis(benzyloxy)cyclohexane-1,2-diol (allo-3a) (entry 1): To a solution of **2a** (38 mg, 0.071 mmol) in MeOH (0.5 mL) was added NaBH_4 (4 mg, 0.1 mmol) at 0 °C. After 30 min, sat aq NaHCO_3 (1 mL) was added, and the whole was extracted with CHCl_3 . The organic layer was washed with water and brine, dried over Na_2SO_4 , and concentrated *in vacuo*. The residue was purified by column chromatography (hexane/EtOAc 3:1) to yield the title compound (31 mg, 81%) as a colorless solid of mp 96–98 °C with $[\alpha]_D^{20} -20.2$ (c 1.00, CHCl_3): IR (neat): 3441, 3063, 3028, 2874, 1497, 1454, 1273, 1092, 1068, 1026, 910. ^1H NMR (55 °C): 2.67 (br s, 1H), 3.47 (br s, 1H), 3.86–3.92 (br m, 5H), 4.15 (br s, 1H), 4.50–4.70 (m, 8H), 7.20–7.35 (m, 20H). ^{13}C NMR: 73.2 (CH_2), 77.1 (CH), 127.7 (CH), 127.8 (CH), 127.9 (CH), 128.3 (CH), 128.36 (CH), 128.44 (CH), 128.5 (CH), 137.9 (C), 138.4 (C). HRMS–ESI m/z : $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_{34}\text{H}_{36}\text{O}_6\text{Na}$, 563.2405; found, 563.2404. Recrystallization from hexane/EtOAc provided colorless needles suitable for X-ray crystallographic analysis; monoclinic $P2_1$, $a = 11.3487(9)$ Å, $b = 7.9412(6)$ Å, $c = 16.2792(13)$ Å, $\alpha = 90.0000^\circ$, $\beta = 99.4718(19)^\circ$, $\gamma = 90.0000^\circ$, $Z = 2$, $R_1 = 0.1000$, $wR_2 = 0.1548$; which determined the stereochemistry. CCDC–1009954 contains the supplementary crystallographic data of this compound. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.

(1S,2S,3R,4R,5R,6R)-3,4,5,6-Tetrakis(benzyloxy)cyclohexane-1,2-diol (chiro-3a) (entry 7): To a solution of **2a** (174 mg, 0.324 mmol) and pyridine (0.11 mL, 1.3 mmol) in CH_2Cl_2 (0.5 mL) was added TESCl (0.15 mL, 0.65 mmol) at –78 °C. After 2 h, sat aq NaHCO_3 (2 mL) was added, and the organic layer was separated. The aqueous layer was extracted with toluene (2 mL $\times$ 4), and the combined organic layers were washed with water (8 mL $\times$ 5) and brine (8 mL), dried over Na_2SO_4 , and evaporated under reduced pressure to give crude *O*-TES inosose **2e** as a yellow oil (230 mg). After removal of residual EtOAc by evaporation with toluene (5 mL), the crude product was dissolved in toluene (2 mL), and *t*- $\text{BuNH}_2 \cdot \text{BH}_3$ (73 mg, 0.81 mmol) was added. After 30 min, 10% HCl (4 mL) and EtOAc (2 mL) were added, and the mixture was vigorously

stirred for 2 h. The aqueous layer was separated and extracted with EtOAc (4 mL $\times$ 2). The combined organic layers were washed with sat aq NaHCO₃ (12 mL) and brine (12 mL), dried over Na₂SO₄, and concentrated. The dr (90:10) was determined by the integration area of ¹H NMR signals at 4.39 (*chiro* 2H) and 3.86–3.93 (*chiro* 2H + *allo* 5H) ppm. The residue was purified by column chromatography (hexane/EtOAc 5:2 to 1:1) to yield the title compound (136 mg, 78%) as a colorless oil with $[\alpha]_D^{25} +2.0$ (c 1.0, CHCl₃): IR (neat): 3410, 3063, 3028, 2916, 2870, 1493, 1454, 1273, 1096, 1057, 1026, 999, 914. ¹H NMR (55 °C): 2.52 (br s, 2H), 3.68 (br d, *J* = 7.0, 2H), 3.74 (br s, 2H), 3.91 (m, 2H), 4.39 (d, *J* = 12.0, 2H), 4.54 (d, *J* = 12.0, 2H), 4.60 (d, *J* = 12.0, 2H), 4.61 (d, *J* = 12.0, 2H), 7.18–7.19 (m, 4H), 7.25–7.33 (m, 16H). ¹³C NMR: 72.6 (CH $\times$ 2), 72.8 (CH₂ $\times$ 2), 73.1 (CH₂), 74.3 (CH $\times$ 2), 78.2 (CH $\times$ 2), 127.70 (CH $\times$ 2), 127.72 (CH), 127.8 (CH), 128.0 (CH $\times$ 2), 128.35 (CH $\times$ 2), 128.45 (CH $\times$ 2), 138.16 (C), 138.23 (C). FABMS *m/z*: 563 (M + Na). HRMS–FAB *m/z*: [M + Na]⁺ calcd for C₃₄H₃₆O₆Na, 563.2404; found, 563.2411. The stereochemistry was determined after the conversion into *D-chiro*-inositol. *allo*-3a (16 mg, 9%) was also obtained as the less polar product.

Scheme 5. (1*R*,2*S*,3*S*,4*R*,5*R*,6*S*)-3,4,5,6-Tetrakis(benzyl-oxy)cyclohexane-1,2-diol (*myo*-3b): To a solution of **2b** (20 mg, 0.037 mmol) in THF (1 mL) was added a 1 M solution of L-selectride in THF (0.07 mL, 0.07 mmol) at –78 °C. After 30 min, water (1 mL) was added, and the mixture was allowed to warm to rt. The whole was extracted with EtOAc (2 mL $\times$ 3), and the combined organic layers were washed with brine, dried over Na₂SO₄, and concentrated. The residue was purified by column chromatography (hexane/EtOAc 2:1) to yield the title compound (18 mg, 93%) as a white solid of mp 142–143 °C with $[\alpha]_D^{20} -22.3$ (c 1.60, CHCl₃). IR (neat): 3588, 3345, 3086, 3063, 3028, 2913, 1497, 1454, 1385, 1358, 1211, 1134, 1088, 1069, 1026, 729. ¹H NMR: 2.43 (br d, *J* = 4.5, 1H), 2.52 (br s, 1H), 3.45–3.50 (m, 3H), 3.86 (t, *J* = 9.5, 1H), 3.97 (t, *J* = 9.5, 1H), 4.20 (t, *J* = 2.5, 1H), 4.70 (d, *J* = 11.5, 1H), 4.71 (d, *J* = 11.5, 1H), 4.75 (d, *J* = 11.0, 1H), 4.84 (d, *J* = 11.0, 1H), 4.85 (d, *J* = 10.5, 1H), 4.91 (d, *J* = 11.0, 1H), 4.92 (d, *J* = 10.5, 1H), 4.95 (d, *J* = 11.0, 1H), 7.26–7.35 (m, 20H). ¹³C NMR: 69.1 (CH), 71.7 (CH), 72.7 (CH₂), 75.6 (CH₂), 75.7 (CH₂), 75.9 (CH₂), 80.0 (CH), 81.3 (CH), 81.6 (CH), 83.2 (CH), 127.6 (CH), 127.8 (CH), 127.88 (CH), 127.93 (CH), 128.0 (CH), 128.36 (CH), 128.39 (CH), 128.5 (CH), 128.6 (CH), 137.7 (C), 138.5 (C), 138.6 (C). HRMS–ESI *m/z*: [M + Na]⁺ calcd for C₃₄H₃₆NaO₆, 563.2404; found, 563.2404. The melting point, specific rotation, and ¹H and ¹³C NMR were in good agreement with those reported (mp 140–142 °C; $[\alpha]_D^{20} -25$ (c 2.7, CHCl₃)).^[40]

(1*R*,2*R*,3*S*,4*R*,5*R*,6*S*)-3,4,5,6-Tetrakis(benzyl-oxy)cyclohexane-1,2-diol (*scyllo*-3b): To a solution of **2b** (38 mg, 70 μ mol) and imidazole (24 mg, 0.35 mmol) in DMF (0.2 mL) cooled in an ice–water bath, was added TESCl (0.03 mL, 0.2 mmol). After removal of the cooling bath, the mixture was stirred for 2 h, and water (1 mL) was added to the mixture. The whole was extracted with ether (1 mL $\times$ 3), and the combined organic layers were washed with brine, dried over Na₂SO₄, and evaporated under reduced pressure. The residue was purified by column chromatography (hexane/EtOAc 14:1) to yield *O*-TES inosose (42 mg, 93%) as a white solid of mp 89–91 °C with $[\alpha]_D^{20} -40$ (c 0.06, CHCl₃): IR (KBr): 3032, 2955, 2920, 2878, 1736, 1458, 1408, 1385, 1366, 1261, 1238, 1211, 1134, 1069, 1026, 814, 737. ¹H NMR: 0.59–0.70 (m, 6H), 0.96 (t, *J* = 8.0, 9H), 3.48 (t, *J* = 10.0, 1H), 3.61 (t, *J* = 10.0, 1H), 3.84 (t, *J* = 10.0, 1H), 4.14 (dd, *J* = 1.5, 10.0, 1H), 4.34 (dd, *J* = 1.5, 10.0, 1H), 7.18–7.22 (m, 2H), 7.25–7.33 (m, 16H), 7.35–7.39 (m, 2H). ¹³C NMR: 4.9 (CH₂), 6.8 (CH₃), 73.2 (CH₂), 75.92 (CH₂), 75.97 (CH₂), 76.04 (CH₂), 78.7 (CH), 81.6 (CH), 82.2 (CH), 82.8 (CH), 82.3 (CH), 127.57 (CH), 127.62 (CH), 127.7 (CH), 127.81 (CH), 127.83 (CH), 127.9 (CH), 128.0 (CH), 128.1 (CH), 128.26 (CH), 128.31 (CH), 128.34 (CH), 128.4 (CH), 137.3 (C), 138.18 (C), 138.26 (C), 202.5 (C).

FABMS *m/z*: 675 (M + Na), 91 (Bn). HRMS–ESI *m/z*: [M + Na]⁺ calcd for C₄₀H₄₈O₆SiNa, 675.3113; found, 675.3112.

To a solution of the above solid (25 mg, 38 μ mol) in toluene (0.25 mL) was added *t*-BuNH₂·BH₃ (8 mg, 0.09 mmol) at rt. After 1 h, 10% HCl (2 mL) and THF (2 mL) were added, and the mixture was vigorously stirred for 15 min. The volume of the mixture was reduced to ca 2 mL by evaporation, and the mixture was extracted with EtOAc. The organic layer was washed with sat aq NaHCO₃ and brine, dried over Na₂SO₄, and concentrated. The residue was purified by column chromatography (hexane/EtOAc 2:1) to yield the title compound (16 mg, 80%) as a white solid of mp 120–123 °C with $[\alpha]_D^{20} -4$ (c 0.1, CHCl₃): IR (KBr): 3372, 3275, 3063, 3005, 2913, 1454, 1400, 1385, 1354, 1261, 1126, 1088, 1069, 1053, 1022, 802, 748. ¹H NMR: 2.53 (br s, 2H), 3.43 (br m, 2H), 3.49 (br m, 2H), 3.58 (br m, 2H), 4.78 (d, *J* = 11.0, 2H), 4.88 (s, 4H), 4.92 (d, *J* = 11.0, 2H), 7.26–7.33 (m, 20H). ¹³C NMR: 73.8, 75.5, 75.9, 82.3, 83.1, 127.7, 127.8, 127.89, 127.94, 128.4, 128.6, 138.3, 138.4. HRMS–ESI *m/z*: [M + Na]⁺ calcd for C₃₄H₃₆NaO₆, 563.2404; found, 563.2404. ¹H and ¹³C NMR were in good agreement with those reported.^[12a,41]

Scheme 6. (1*R*,2*S*,3*R*,4*S*,5*S*,6*R*)-3,6-Bis(*tert*-butyldi-phenylsiloxy)-4,5-(isopropylidenedioxy)cyclohexane-1,2-diol (*allo*-13c): To a solution of **12c** (20 mg, 0.029 mmol) in THF (0.5 mL) cooled in an ice–water bath, was added a 1 M solution of BH₃·THF in THF (0.060 mL, 0.060 mmol). After 7 h, another portion of a 1 M solution of BH₃·THF in THF (0.015 mL, 0.015 mmol) was added. After 1.5 h, water (2 mL) was added, and the whole was extracted with EtOAc (2 mL $\times$ 3). The combined organic layers were washed with brine, dried over Na₂SO₄, and concentrated. The borane-derived impurities were removed by column chromatography (hexane/EtOAc 19:1) to yield a mixture of the title compound with *neo*-13c as a colorless oil (19 mg, 93%) with $[\alpha]_D^{20} -20$ (c 0.74, CHCl₃): IR (neat): 3549, 3530, 3071, 3051, 2959, 2897, 1474, 1427, 1381, 1369, 1227, 1142, 1111, 1072, 1045, 1007, 880, 849, 822, 795, 760. ¹H NMR: 1.04 (s, 9H), 1.10 (s, 9H), 1.43 (s, 3H), 1.46 (s, 3H), 1.89 (d, *J* = 10.5, 1H), 2.81 (d, *J* = 9.0, 1H), 3.43 (dt, *J* = 8.5, 3.0, 1H), 3.76 (dt, *J* = 10.0, 3.0, 1H), 4.08 (dd, *J* = 2.0, 10.0), 4.33 (dd, *J* = 2.5, 10.0, 1H), 4.44 (t, *J* = 3.0, 1H), 4.71 (br t, *J* = 3.0, 1H), 7.30–7.50 (m, 14H), 7.61 (m, 2H), 7.70–7.80 (m, 4H). ¹³C NMR: 19.2 (C), 19.4 (C), 26.9 (CH₃), 27.07 (CH₃), 27.12 (CH₃ $\times$ 2), 68.3 (CH), 69.8 (CH), 72.5 (CH), 74.1 (CH), 74.4 (CH), 75.7 (CH), 111.0 (C), 127.5 (CH), 127.6 (CH), 127.8 (CH), 127.9 (CH), 129.8 (CH), 130.0 (CH), 130.1 (CH), 132.0 (C), 132.7 (C), 133.4 (C), 133.6 (C), 135.7 (CH), 136.0 (CH), 136.1 (CH), 136.5 (CH). HRMS *m/z*: [M + Na]⁺ calcd for C₄₁H₅₂NaO₆Si₂, 719.3195; found, 719.3195. The dr (89:11) was determined by the integration area of ¹H NMR signals at 4.71 and 4.58 ppm. The stereochemistry was tentatively assigned as drawn.

(1*R*,2*R*,3*R*,4*S*,5*S*,6*R*)-4,5-(Isopropylidenedioxy)-3,6-bis(*tert*-butyldiphenylsiloxy)cyclohexane-1,2-diol (*neo*-13c): To a solution of **12c** (235 mg, 0.338 mmol) and 2,6-lutidine (0.20 mL, 1.7 mmol) in CH₂Cl₂ (0.5 mL) cooled at –78 °C, was added TESOTf (0.23 mL, 1.0 mmol). After 14.5 h, water (2 mL) was added, and the mixture was allowed to warm to rt. The aqueous layer was separated and extracted with CHCl₃ (2 mL $\times$ 3). The combined organic layers were washed with water (6 mL $\times$ 3), dried over Na₂SO₄, and concentrated. The residue was purified by column chromatography (hexane/EtOAc 98:2) to yield 6*O*-TES inosose (254 mg, 93%) as a white solid of mp 78–80 °C with $[\alpha]_D^{20} -20.5$ (c 1.00, CHCl₃). IR (neat): 3075, 3051, 2955, 2932, 3859, 2878, 1751, 1474, 1462, 1427, 1381, 1369, 1231, 1180, 1134, 1115, 1059, 1049, 1022, 8445, 822, 741. ¹H NMR: 0.14 (q, *J* = 8.0, 6H), 0.61 (t, *J* = 8.0, 9H), 0.99 (s, 9H), 1.10 (s, 9H), 1.41 (s, 3H), 1.47 (s, 3H), 4.19 (dd, *J* = 2.5, 10.0, 1H), 4.53 (dd, *J* = 2.0, 10.0, 1H), 4.58 (dd, *J* = 2.0, 3.5, 1H), 4.61 (d, *J* = 2.5, 1H), 4.64 (d, *J* = 3.5, 1H), 7.29–7.45 (m, 12H), 7.59–7.64 (m, 4H), 7.67–7.72 (m, 4H). ¹³C NMR: 4.0 (CH₂), 6.5 (CH₃), 19.3 (C), 19.9 (C), 26.8 (CH₃), 27.0 (CH₃), 27.2 (CH₃), 71.9

(CH), 74.2 (CH), 74.6 (CH), 75.4 (CH), 75.7 (CH), 112.7 (C), 126.9 (CH), 127.3 (CH), 127.5 (CH), 127.6 (CH), 129.0 (CH), 129.5 (CH), 129.9 (CH), 130.0 (CH), 132.3 (C), 132.7 (C × 2), 133.1 (C), 135.9 (CH), 136.2 (CH), 136.4 (CH), 136.6 (CH), 203.9 (C). HRMS-ESI m/z : [M + Na]⁺ calcd for C₄₇H₆₄NaO₆Si₂, 831.3903; found, 831.3903.

To a solution of the above solid (20 mg, 25 μmol) in toluene (0.15 mL), was added *t*-BuNH₂·BH₃ (6 mg, 0.06 mmol) at rt. After 30 min, the mixture was evaporated to give a crude material as a cloudy oil. The oil was dissolved in a 1:1 mixture of THF/pyridine (0.8 mL) cooled in an ice–water bath, HF·pyridine complex (0.2 mL) was added. The cooling bath was removed and the mixture was stirred for 45 min. The mixture was cooled in the ice–water bath, and the reaction was quenched by the addition of sat aq NaHCO₃ (2 mL). The whole was extracted with EtOAc (2 mL × 3), and the combined organic layers were washed with brine (6 mL), dried over Na₂SO₄, and concentrated *in vacuo*. The residual pyridine was removed by evaporation with toluene (10 mL × 2). The dr (96:4) was determined by the integration area of ¹H NMR signals at 4.58 and 4.71 ppm. The residue was purified by column chromatography (hexane/EtOAc 95:5) to give a 96:4 diastereomeric mixture of the title compound (17 mg, 97%) as a white solid of mp 46–48 °C with [α]_D²⁵ +20 (c 0.83, CHCl₃) (lit.^[12c] mp 61–64 °C, [α]_D²⁵ +13.7 (c 1.0, CHCl₃)): IR (neat): 3549, 3071, 3051, 3013, 2986, 2969, 2932, 2859, 1427, 1381, 1369, 1219, 1157, 1111, 1042, 1007, 837, 760. ¹H NMR: 1.08 (s, 18H), 1.42 (s, 9H), 3.66 (br s, 2H), 4.12 (br s, 2H), 4.58 (br s, 2H), 7.33–7.45 (m, 12H), 7.66 (m, 4H), 7.78 (m, 4H). ¹³C NMR: 19.6 (C), 27.06 (CH₃), 27.13 (CH₃), 67.0 (CH), 72.8 (CH), 74.5 (CH), 111.4 (C), 127.5 (CH), 127.7 (CH), 129.8 (CH), 129.9 (CH), 132.6 (C), 134.1 (C), 136.0 (CH), 136.5 (CH). EIMS m/z : 639 (M – *t*-Bu). ¹H and ¹³C NMR were in good agreement with those reported.^[12c]

Scheme 7. (1*S*,2*R*,3*R*,4*R*,5*S*,6*R*)-2-Acetamido-3,4,5,6-tetrakis(benzyloxy)cyclohexyl acetate (14a): To a stirred solution of **2a** (160 mg, 0.0299 mmol) in EtOH (1.5 mL), were added pyridine (0.16 mL, 2.0 mmol) and MeONH₂·HCl (125 mg, 1.50 mmol) at rt. After 30 min, the solution was diluted with EtOAc, washed with H₂O and brine, dried over Na₂SO₄, and concentrated *in vacuo*. From the residue, the remaining pyridine was removed by three-time evaporation with toluene to give crude *O*-methyl oxime as a yellow oil (178 mg).

The above oil was dissolved in THF (0.5 mL + 0.25 mL wash × 2) and added to a suspension of NaOMe (162 mg, 3.00 mmol) and LiAlH₄ (170 mg, 4.48 mmol) at –78 °C. After 30 min, the cooling bath was removed, and the mixture was allowed to warm up to rt. After 30 min, the mixture was heated at 65 °C for 30 min and then cooled to rt. To the mixture, H₂O was dropwise added until no gas evolution occurred. The whole was filtered through celite, which was successively washed with CHCl₃. The combined filtrate was concentrated *in vacuo* to give a crude mixture of **4a** and *epi-4a* as a yellow oil.

The above oil was dissolved in CH₂Cl₂ (3 mL), and pyridine (0.48 mL, 5.9 mmol), Ac₂O (0.57 mL, 6.0 mmol), and DMAP (4 mg, 0.03 mmol) were added. The mixture was stirred at rt for 1.5 h and diluted with EtOAc. The mixture was washed with 10% HCl, H₂O, sat aq NaHCO₃, and brine, dried over Na₂SO₄, and concentrated *in vacuo*. The resulting oil was purified by column chromatography (hexane/EtOAc 3:2 to 4:6) to give the title compound (127 mg, 68%) as a yellow oil with [α]_D²⁰ +23 (c 0.33, CHCl₃): IR (neat): 3294, 3063, 3028, 2924, 2870, 1736, 1667, 1551, 1524, 1497, 1454, 1373, 1234, 1103, 1072, 1026, 756. ¹H NMR: 1.86 (s, 3H), 2.01 (s, 3H), 3.57 (dd, *J* = 1.5, 10.0, 1H), 3.67 (br m, 1H), 3.71 (br m, 1H), 3.90 (dd, *J* = 2.5, 10.0, 1H), 4.32 (br d, *J* = 12.0, 1H), 4.36–4.42 (m, 2H), 4.45–4.57 (m, 4H), 4.67 (d, *J* = 12.0, 1H), 4.68 (d, *J* = 12.0, 1H), 5.12 (t, *J* = 10.0, 1H), 5.12 (br s, 1H), 7.15–7.19 (m, 4H), 7.25–7.36 (m, 16H). ¹³C NMR: 20.9 (CH₃), 23.4 (CH₃), 71.8 (CH₂), 73.0 (CH), 73.1 (CH₂), 73.2 (CH₂), 73.5 (CH₃), 73.6 (CH × 2), 75.0 (CH), 76.5 (CH), 77.2

(CH), 127.65 (CH), 127.73 (CH), 127.8 (CH), 127.9 (CH), 128.1 (CH), 128.31 (CH), 128.34 (CH), 128.37 (CH), 128.43 (CH), 138.0 (C), 138.2 (C), 170.1 (C), 171.3 (C). HRMS-ESI m/z : [M + K]⁺ calcd for C₃₈H₄₁KNO₇, 662.2515; found, 662.2518. The stereochemistry was determined based on the *trans*-diaxial couplings of 1-H (5.12 ppm) with 2-H and 6-H (both *J* = 10 Hz) as shown in Scheme 7. In addition, *epi-14a* (*vide infra*) was isolated as a minor product (20 mg, 11%).

(1*S*,2*S*,3*R*,4*R*,5*S*,6*R*)-2-Acetamido-3,4,5,6-tetrakis(benzyloxy)cyclohexyl acetate (*epi-14a*): To a solution of **2a** (109 mg, 0.203 mmol) in pyridine (2 mL), was added HONH₂·HCl (71 mg, 1.0 mmol), and the solution was stirred at rt for 1.5 h. The solution was diluted with EtOAc (20 mL), washed with H₂O (20 mL × 3) and brine, dried over Na₂SO₄, and concentrated *in vacuo* to give crude oxime as a pale brown oil (139 mg).

The above oil was dissolved in CH₂Cl₂ (2 mL), and pyridine (0.33 mL, 4.1 mmol), DMAP (3 mg, 0.02 mmol), and Ac₂O (0.38 mL, 4.0 mmol) were added to the stirred solution cooled in an ice–water bath. The mixture was stirred for 1 h, and the reaction was quenched by the addition of H₂O (10 mL). The whole was extracted with CHCl₃ (20 mL × 3), and the combined organic layers were washed with brine (20 mL), dried over Na₂SO₄, and concentrated *in vacuo*. The residual pyridine was removed by three-time evaporation with toluene (10 mL × 3) to give crude *O*-acetyl oxime as a yellow oil (131 mg).

The above oil was dissolved in EtOH (2 mL), and NiCl₂·6H₂O (97 mg, 0.41 mmol) was added. To the mixture cooled in an ice–water bath, NaBH₄ (78 mg, 2.1 mmol) was portion-wise added, and the cooling bath was removed. After 1.5 h, the mixture was cooled in an ice–water bath, and NaBH₄ (78 mg, 2.1 mmol) was portion-wise added again. The mixture was stirred at rt for 2 h and diluted with EtOAc (20 mL). After addition of H₂O (20 mL), the whole was filtered through celite pad, which was successively washed with EtOAc. The organic layer was separated, and the aqueous layer was extracted with EtOAc (20 mL × 3). The combined organic layers were washed with H₂O and brine, dried over Na₂SO₄, and concentrated *in vacuo* to give crude *epi-4a* as a pale yellow oil (115 mg).

The above oil was dissolved in CH₂Cl₂ (2 mL), and pyridine (0.16 mL, 2.0 mmol), Ac₂O (0.19 mL, 2.0 mmol), and DMAP (2 mg, 0.02 mmol) were added to the stirred solution cooled in an ice–water bath. After 1.5 h, the reaction was quenched by the addition of H₂O (5 mL), and the whole was extracted with CHCl₃ (10 mL × 3). The combined organic layers were dried over Na₂SO₄ and concentrated *in vacuo* to give crude product as a pale brown oil (128 mg). This oil was purified by column chromatography (hexane/EtOAc 2:1) to give the title compound (65 mg, 51%) as a colorless oil with [α]_D²⁰ –18.2 (c 1.00, CHCl₃): IR (neat): 3410, 3086, 3063, 3028, 3009, 2059, 2924, 2870, 1734, 1674, 1512, 1497, 1454, 1431, 1369, 1323, 1234, 1099, 1053, 1026, 914, 802, 752. ¹H NMR (–20 °C): 1.81 (s, 3H), 2.04 (s, 3H), 3.78 (dd, *J* = 3.0, 4.0, 1H), 3.84 (dd, *J* = 3.0, 11.0, 1H), 3.86 (m, 1H), 3.94 (dd, *J* = 3.0, 4.5, 1H), 4.36 (d, *J* = 11.5, 1H), 4.46 (d, *J* = 11.0, 1H), 4.47 (d, *J* = 12.0, 1H), 4.52 (d, *J* = 12.0, 1H), 4.62 (d, *J* = 12.0, 1H), 4.66 (d, *J* = 11.5, 1H), 4.67 (d, *J* = 11.0, 1H), 4.68 (d, *J* = 12.0, 1H), 5.04 (ddt, *J* = 1.0, 9.0, 4.5, 1H), 5.22 (dd, *J* = 4.0, 11.0, 1H), 6.90 (d, *J* = 9.0, 1H), 7.18–7.21 (m, 4H), 7.29–7.40 (m, 16H). ¹³C NMR: 21.0 (CH₃), 23.4 (CH₃), 48.1 (CH), 70.7 (CH₂), 70.8 (CH), 71.7 (CH), 73.0 (CH₂), 73.5 (CH₂), 74.1 (CH₂), 74.5 (CH), 74.4 (CH), 79.1 (CH), 127.5 (CH), 127.6 (CH), 127.7 (CH), 127.8 (CH), 128.1 (CH), 127.6 (CH), 128.27 (CH), 128.30 (CH), 128.32 (CH), 128.5 (CH), 137.5 (C), 137.87 (C), 137.90 (C), 138.4 (C), 170.4 (C), 170.5 (C); FABMS m/z : 624 (M + H), 91 (Bn). HRMS-FAB m/z : [M + H]⁺ calcd for C₃₈H₄₂NO₇, 624.2956; found, 624.2949. The stereochemistry was determined based on the *trans*-diaxial coupling (*J* = 11.0 Hz) between 2-H and 3-H (3.84 and 5.22 ppm, respectively) as shown in Scheme 7.

(1R,2R,3R,4R,5R)-2,3,4,5-Tetrakis(benzyloxy)cyclohexanol (5a): To a solution of **2a** (540 mg, 1.00 mmol), DMAP (18 mg, 0.15 mmol), and pyridine (0.28 mL, 3.5 mmol) in CH₂Cl₂ (10 mL) cooled in an ice–water bath, was added *O*-phenyl chlorothioformate (0.42 mL, 3.0 mmol). After 2.5 h, MeOH (2 mL) was added, and the mixture was stirred for another 10 min and evaporated. To the residue, EtOAc and water were added, and the aqueous layer was separated and extracted 3 times with EtOAc. The combined organic layers were washed with brine, dried over Na₂SO₄, and concentrated under reduced pressure. To the resulting orange oil (1.1 g), containing *O*-phenoxythiocarbonyl inosose, was used in the next reaction without purification. The crude inosose was purified by column chromatography (hexane/EtOAc 95:5) to provide a pale yellow solid of mp 88–90 °C with $[\alpha]_D^{20}$ –53.0 (*c* 1.21, CHCl₃); IR (neat): 3086, 3063, 3028, 2920, 2874, 1751, 1589, 1493, 1454, 1362, 1285, 1223, 1207, 1107, 1049, 1045, 1026, 1003, 914, 864, 818, 752. ¹H NMR: 3.82 (dd, *J* = 3.0, 4.0, 1H), 3.93 (dd, *J* = 3.0, 4.0, 1H), 4.19 (dd, *J* = 3.0, 11.0, 1H), 4.40 (d, *J* = 12.0, 1H), 4.43 (d, *J* = 12.0, 1H), 4.50 (d, *J* = 12.0, 1H), 4.53 (d, *J* = 12.0, 1H), 4.62 (d, *J* = 3.0, 1H), 4.71 (d, *J* = 12.0, 1H), 4.73 (d, *J* = 12.0, 1H), 4.78 (d, *J* = 12.0, 1H), 4.78 (d, *J* = 12.0, 1H), 4.90 (d, *J* = 12.0, 1H), 6.15 (d, *J* = 11.0, 1H), 7.09–7.44 (m, 25H). ¹³C NMR: 72.8 (CH₂), 73.7 (CH₂), 73.8 (CH₂), 73.9 (CH₂), 74.9 (CH), 77.5 (CH), 78.8 (CH), 80.9 (CH), 85.6 (CH), 121.9 (CH), 126.6 (CH), 127.76 (CH), 127.78 (CH), 127.83 (CH), 127.90 (CH), 127.98 (CH), 128.3 (CH), 128.4 (CH), 128.5 (CH), 129.5 (CH), 137.5 (C), 137.7 (C), 153.6 (C), 194.8 (C), 197.0 (C). FABMS *m/z*: 697 (M + Na)⁺, 91 (Bn). HRMS–ESI *m/z*: [M + Na]⁺ calcd for C₄₁H₃₈O₇Sn, 697.2231; found, 697.2233.

To a solution of the above crude material in toluene (10 mL), were added Bu₃SnH (0.40 mL, 1.5 mmol) and AIBN (16 mg, 0.097 mmol), and the solution was heated at 80 °C. After 2 h, another portion of AIBN (16 mg, 0.097 mmol) was added. After 1.5 h, AIBN (16 mg, 0.097 mmol) and Bu₃SnH (0.40 mL, 1.5 mmol) were added again. After 1 h, the mixture was evaporated, and the resulting yellow oil was purified by column chromatography (hexane/EtOAc 95:5) to yield deoxyinosose (345 mg, 66% in 2 steps) as a pale yellow oil with $[\alpha]_D^{20}$ –61.3 (*c* 0.45, CHCl₃); IR (neat): 3086, 3063, 3028, 2924, 2870, 1732, 1496, 1454, 1366, 1327, 1312, 1265, 1215, 1111, 1026, 1003, 914, 802, 752. ¹H NMR: 2.75 (ddd, *J* = 1.5, 5.0, 13.0, 1H), 2.84 (dd, *J* = 11.0, 13.0, 1H), 3.93 (ddd, *J* = 1.5, 2.5, 5.0, 1H), 3.99 (dd, *J* = 3.5, 5.0, 1H), 4.06 (ddd, *J* = 2.5, 5.0, 11.0, 1H), 4.431 (d, *J* = 12.0, 1H), 4.433 (d, *J* = 3.5, 1H), 4.44 (d, *J* = 12.0, 1H), 4.47 (d, *J* = 12.0, 1H), 4.52 (d, *J* = 12.0, 1H), 4.55 (d, *J* = 12.0, 1H), 4.74 (d, *J* = 12.0, 1H), 4.75 (d, *J* = 12.0, 1H), 4.87 (d, *J* = 12.0, 1H), 7.16–7.19 (m, 4H), 7.27–7.37 (m, 16H). ¹³C NMR: 42.2 (CH₂), 71.4 (CH), 72.6 (CH), 73.4 (CH), 73.5 (CH), 75.72 (CH), 75.75 (CH), 78.1 (CH), 81.5 (CH), 127.5 (CH), 127.68 (CH), 127.73 (CH), 127.76 (CH), 127.79 (CH), 128.31 (CH), 128.38 (CH), 128.42 (CH), 137.8 (C), 138.0 (C), 138.05 (C), 138.14 (C), 204.6 (C). HRMS–ESI *m/z*: [M + Na]⁺ calcd for C₃₄H₃₄O₅Na, 545.2299; found, 545.2299.

To a solution of the above oil (9.0 mg, 17 μmol) in MeOH (0.2 mL) cooled in an ice–water bath, was added NaBH₄ (1.7 mg, 45 μmol), and the mixture was stirred for 40 min. After addition of sat aq NH₄Cl, the whole was extracted with EtOAc (1.5 mL × 4). The combined organic layers were washed with brine (4.5 mL) and evaporated. The residue was purified by column chromatography (hexane/EtOAc 9:2) to give the title compound (8.3 mg, 93%) as a pale yellow solid of mp 91–92.5 °C with $[\alpha]_D^{20}$ –24 (*c* 0.30, CHCl₃); IR (KBr): 3314, 3086, 3063, 3028, 2955, 2928, 2855, 2878, 2739, 2677, 1496, 1454, 1435, 1315, 1261, 1207, 1150, 1099, 1084, 1065, 1026, 1084, 914, 868, 802, 745. ¹H NMR (60 °C): 1.85–1.95 (br s, 1H), 1.98 (ddd, *J* = 3.5, 7.5, 11.5, 1H), 3.86–3.88 (m, 2H), 3.95 (dd, *J* = 2.5, 7.5, 1H), 3.97 (br s, 1H), 4.09 (br s, 1H), 4.55–4.72 (m, 7H), 4.77 (br s, 1H), 7.21–7.35 (m, 20H). ¹³C NMR: 32.4 (CH₂), 71.5 (CH₂), 72.5 (CH × 3), 73.0 (CH₂), 73.9 (CH₂), 79.4 (CH × 2), 127.6 (CH), 127.66

(CH), 127.72 (CH), 127.8 (CH), 127.9 (CH), 128.39 (CH), 128.41 (CH), 128.49 (CH), 128.51 (CH), 138.7 (C), 138.8 (C), 138.9 (C). HRMS–ESI *m/z*: [M + Na]⁺ calcd for C₃₄H₃₆O₅Na, 547.2455; found, 547.2453. The stereochemistry was determined at the stage of **15a**.

(1R,2R,3S,4R,5R)-2,3,4,5-Tetrakis(benzyloxy)cyclohexyl acetate (15a): To a solution of **5a** (5.9 mg, 11 μmol), DMAP (1 mg, 8 μmol), and Et₃N (0.01 mL, 0.07 mmol) in CH₂Cl₂ (0.1 mL) cooled in an ice–water bath, was added Ac₂O (0.01 mL, 0.1 mmol), and the mixture was stirred for 1 h. After addition of water (2 mL), the whole was extracted three times with CHCl₃. The combined organic layers were washed with brine, dried over Na₂SO₄, and concentrated *in vacuo*. The residue was purified by column chromatography (hexane/EtOAc 95:5) to give the title compound (4.0 mg, 64%) as a pale yellow oil with $[\alpha]_D^{20}$ –3.9 (*c* 1.00, CHCl₃); IR (neat): 3088, 3063, 3030, 2933, 2903, 2868, 1738, 1497, 1454, 1368, 1346, 1240, 1207, 1159, 1094, 1070, 1051, 1026, 735. ¹H NMR (60 °C): 1.93–2.05 (m, 2H), 1.97 (s, 3H), 3.91–3.94 (m, 2H), 3.98 (dd, *J* = 2.5, 9.0, 1H), 4.12 (br m, 1H), 4.64 (d, *J* = 11.5, 1H), 4.66 (s, 2H), 4.69 (d, *J* = 11.5, 1H), 4.71 (d, *J* = 11.5, 1H), 4.76 (d, *J* = 11.5, 1H), 4.81 (d, *J* = 11.5, 1H), 5.12 (ddd, *J* = 2.5, 4.0, 11.0, 1H). ¹³C NMR: 21.3 (CH₃), 28.4 (CH₂), 69.9 (CH), 71.6 (CH₂), 72.5 (CH), 73.0 (CH₂), 73.3 (CH₂ × 2), 74.4 (CH₂), 76.9 (CH), 79.1 (CH), 79.4 (CH), 127.45 (CH), 127.49 (CH), 127.54 (CH), 127.7 (CH), 127.82 (CH), 127.84 (CH), 128.27 (CH), 128.33 (CH), 128.4 (CH), 138.6 (C), 139.0 (C), 139.1 (C), 139.2 (C), 170.6 (C). HRMS–ESI *m/z*: [M + K]⁺ calcd for C₃₆H₃₆KO₆, 605.2300; found, 605.2300. The stereochemistry was determined based on the coupling constant (2.5, 4.0, and 11.0 Hz) of the methine proton that the AcO group attaches on, indicating equatorial orientation of the AcO group and axial orientation of the adjacent BnO groups, as shown in Scheme 7.

(1R,2R,3R,4R,5R,6S)-2,3,4,5-Tetrakis(benzyloxy)-6-methoxycyclohexanol (6a): To a solution of **2a** (107 mg, 0.198 mmol) and proton sponge (85 mg, 0.040 mmol) in CH₂Cl₂ (2 mL), was added Me₃O·BF₄ (59 mg, 0.40 mmol) at rt. After 14 h, water (8 mL) was added, and the whole was extracted with CHCl₃ (8 mL × 2). The combined organic layers were washed with brine (16 mL), dried over Na₂SO₄, and concentrated under reduced pressure. The residue was purified by column chromatography (hexane/EtOAc 5:1) to yield *O*-Me inosose (103 mg, 90%) as a colorless oil with $[\alpha]_D^{20}$ –39.0 (*c* 1.00, CHCl₃); IR (neat): 3395, 3086, 3062, 3028, 3086, 3005, 2920, 2873, 1959, 1871, 1743, 1654, 1543, 1497, 1454, 1385, 1366, 1323, 1026, 1150, 1111, 1026, 957, 918, 737. ¹H NMR: 3.58 (s, 3H), 3.75 (dd, *J* = 3.5, 4.0, 1H), 3.88 (dd, *J* = 3.0, 4.0, 1H), 3.90 (dd, *J* = 3.5, 10.0, 1H), 4.18 (dd, *J* = 1.0, 10.0, 1H), 4.36 (d, *J* = 12.0, 1H), 4.43 (d, *J* = 12.0, 1H), 4.48 (dd, *J* = 1.0, 3.0, 1H), 4.49 (d, *J* = 12.0, 1H), 4.68 (d, *J* = 12.0, 1H), 4.73 (d, *J* = 12.0, 1H), 4.80 (d, *J* = 12.0, 1H), 4.88 (d, *J* = 12.0, 1H), 7.08–7.16 (m, 4H), 7.25–7.36 (m, 16H). ¹³C NMR: 59.9 (CH₃), 72.5 (CH₂), 73.3 (CH₂), 73.7 (CH₂), 74.0 (CH₂), 75.3 (CH), 77.2 (CH), 80.6 (CH), 80.7 (CH), 85.7 (CH), 127.6 (CH), 127.71 (CH), 127.73 (CH), 127.8 (CH), 127.9 (CH), 128.2 (CH), 128.3 (CH), 128.4 (CH), 137.7 (C), 137.8 (C), 137.9 (C), 138.5 (C), 202.8 (C). FABMS *m/z*: 575 (M + Na), 329, 136, 91 (Bn). HRMS–FAB *m/z*: [M + Na]⁺ calcd for C₃₅H₃₆O₆Na, 575.2404; found, 575.2415.

To a solution of the above oil (9.7 mg, 0.018 mmol) in MeOH (0.2 mL) cooled in an ice–water bath, was added NaBH₄ (2 mg, 0.05 mmol). After 30 min, sat aq NH₄Cl (1.5 mL) was added, and the whole was extracted with EtOAc (1.5 mL × 5). The combined organic layers were washed with brine (8 mL), dried over Na₂SO₄, and concentrated under reduced pressure. The residue was purified by column chromatography (hexane/EtOAc 2:1) to yield the title compound (8.4 mg, 86%) as a colorless oil with $[\alpha]_D^{20}$ –13 (*c* 0.42, CHCl₃); IR (neat): 3502, 3086, 3063, 3028, 3086, 3009, 2924, 2874, 1497, 1454, 1358, 1261, 1215, 1092, 1041, 1026, 910, 802, 748. ¹H NMR (–

20 °C): 3.50 (dd, $J = 2.5, 10.0$, 1H), 3.57 (s, 3H), 3.64 (br s, 1H), 3.66 (br s, 1H), 3.77 (br s, 1H), 3.94 (dd, $J = 2.0, 10.0$, 1H), 4.34 (d, $J = 12.0$, 1H), 4.37 (d, $J = 12.0$, 1H), 4.45 (d, $J = 12.0$, 1H), 4.47 (br s, 1H), 4.52 (d, $J = 12.0$, 1H), 4.58 (d, $J = 12.0$, 1H), 4.63 (d, $J = 12.0$, 1H), 4.68 (d, $J = 12.0$, 1H), 4.82 (d, $J = 12.0$, 1H), 7.05–7.45 (m, 20H). ^{13}C NMR (–20 °C): 58.0 (CH₃), 68.6 (CH), 70.4 (CH₂), 72.9 (CH), 73.2 (CH₂), 73.6 (CH₂ × 2), 74.8 (CH), 75.7 (CH), 77.8 (CH), 79.8 (CH), 127.5 (CH), 127.6 (CH), 127.69 (CH), 127.78 (CH), 127.84 (CH), 127.9 (CH), 128.0 (CH), 128.29 (CH), 128.34 (CH), 128.4 (CH), 137.0 (C), 137.8 (C), 137.9 (C), 138.7 (C). HRMS–ESI m/z : $[\text{M} + \text{Na}]^+$ calcd for C₃₅H₃₈O₆Na, 577.2561; found, 577.2568. The stereochemistry was determined based on the *trans*-diaxial coupling ($J = 10.0$ Hz) between 5-H and 6-H (3.94 and 3.50 ppm, respectively) as shown in Scheme 7.

(1R,2R,3R,4R,5S,6S)-3,4,5,6-Tetrakis(benzyloxy)-1-methylcyclohexane-1,2-diol (7a): A 1.5 M solution of MeLi·LiBr in THF (0.23 mL, 0.35 mmol) was diluted with Et₂O (0.4 mL) and cooled at –78 °C. A solution of **2a** (62 mg, 0.12 mmol) in Et₂O (0.4 mL + 0.2 mL wash × 2) was added, and the cooling bath was replaced with an ice-water bath. After 2 h, sat aq NH₄Cl (2 mL) was added, and the whole was extracted with EtOAc (2 mL × 4). The combined organic layers were washed with brine (8 mL), dried over Na₂SO₄, and concentrated under reduced pressure. The residue was purified by column chromatography (hexane/EtOAc 3:1 to 2:1) to yield the title compound (57 mg, 89%) as a colorless oil with $[\alpha]_D^{20} +15.8$ (c 1.00, CHCl₃); IR (neat): 3483, 3086, 3063, 3028, 3005, 2982, 2932, 2870, 1956, 1871, 1655, 1605, 1543, 1497, 1420, 1385, 1366, 1331, 1250, 1207, 1142, 1099, 1065, 1026, 964, 914, 802, 748. ^1H NMR: 1.34 (s, 3H), 2.41 (br s, 1H), 3.49 (br s, 1H), 3.60–3.78 (m, 4H), 3.82 (br s, 1H), 4.43–4.42 (m, 2H), 4.45–4.63 (m, 5H), 4.71 (d, $J = 12.0$, 1H), 7.09–7.19 (m, 4H), 7.23–7.39 (m, 16H). ^{13}C NMR: 22.1 (CH₃), 72.9 (CH₂), 73.1 (CH₂), 73.2 (CH₂), 73.7 (CH₂), 74.2 (CH × 2), 76.4 (CH), 77.2 (CH), 77.9 (CH), 99.8 (C), 127.6 (CH), 127.7 (CH), 127.9 (CH), 128.0 (CH), 128.1 (CH), 128.35 (CH), 128.4 (CH), 128.5 (CH), 137.1 (C), 137.7 (C), 138.2 (C), 138.5 (C). FABMS m/z : 577 (M + Na), 525, 481, 437, 393, 349, 305, 243, 183, 91 (Bn). HRMS–FAB m/z : $[\text{M} + \text{Na}]^+$ calcd for C₃₅H₃₆O₆Na, 577.2561; found, 577.2565. The stereochemistry was determined at the stage of **16a**.

(1R,2R,3R,4R,5S,6S)-3,4,5,6-Tetrakis(benzyloxy)-1,2-isopropylidenedioxy-1-methylcyclohexane (16a): To a solution of **7a** (66 mg, 0.12 mmol) in 2,2-dimethoxypropane (2.0 mL, 16 mmol) was added TsOH·H₂O (5 mg, 0.03 mmol) at rt. The mixture was stirred for 2 h, and sat aq NaHCO₃ (10 mL) was added. The whole was extracted with EtOAc (10 mL × 3), and the combined organic layers were washed with brine (30 mL), dried over Na₂SO₄, and concentrated under reduced pressure. The residue was purified by column chromatography (hexane/EtOAc 96:4) to yield the title compound (51 mg, 93%) as a colorless oil with $[\alpha]_D^{25} -27.2$ (c 1.44, CHCl₃); IR (neat): 3086, 3062, 3028, 3005, 2982, 2932, 2889, 2878, 1497, 1454, 1377, 1308, 1258, 1242, 1211, 1188, 1115, 1088, 1072, 1026, 984, 918, 864, 752, 733. ^1H NMR: 1.36 (s, 3H), 1.38 (s, 3H), 1.39 (s, 3H), 3.65 (d, $J = 3.0$, 1H), 3.87 (dd, $J = 3.0, 6.5$, 1H), 4.08 (d, $J = 5.0$, 1H), 4.10 (dd, $J = 3.5, 6.5$, 1H), 4.19 (dd, $J = 3.5, 5.0$, 1H), 4.57 (s, 2H), 4.65 (d, $J = 12.0$, 1H), 4.67 (d, $J = 12.0$, 1H), 4.68 (d, $J = 12.0$, 1H), 4.72 (d, $J = 12.0$, 1H), 4.74 (d, $J = 12.0$, 1H), 4.76 (d, $J = 12.0$, 1H), 7.23–7.37 (m, 20H). ^{13}C NMR: 26.0 (CH₃), 27.0 (CH₃), 27.6 (CH₃), 72.3 (CH₂), 72.89 (CH₂), 72.92 (CH₂), 74.7 (CH₂), 76.5 (CH), 76.9 (CH), 77.2 (CH), 81.0 (CH), 81.2 (C), 82.2 (CH), 109.7 (C), 127.31 (CH), 127.32 (CH), 127.34 (CH), 127.36 (CH), 127.49 (CH), 127.52 (CH × 2), 127.57 (CH), 128.07 (CH), 128.11 (CH), 128.15 (CH), 128.18 (CH), 138.6 (C × 2), 138.70 (C), 138.77 (C). FABMS m/z : 617 (M + Na), 329, 176, 91 (Bn). HRMS–FAB m/z : $[\text{M} + \text{Na}]^+$ calcd for C₃₈H₄₂NaO₆, 617.2874; found, 617.2873. The relative configuration was determined by NOESY correlation

between angular CH₃ (1.36 ppm) and H (4.05 ppm) as shown in Scheme 7.

Scheme 8. (2R,3S,4R,5S,6S)-2,3,4,5,6-pentahydroxycyclohexanone (allo-2-inosose): To a solution of **2a** (819 mg, 1.52 mmol) in MeOH (10 mL), was added 10% Pd/C (wetted with 55% water, 485 mg, 0.20 mmol), and the mixture was stirred under H₂ atmosphere at rt for 24 h. After addition of H₂O (10 mL) and activated charcoal (500 mg), the mixture was stirred for 20 min and filtered through filter paper, which was washed with H₂O (10 mL × 3). The combined filtrate was concentrated *in vacuo* to give the title compound (228 mg, 84%) as colorless blocks of mp 180–182 °C (H₂O/*i*-PrOH) with $[\alpha]_D^{20} +75.1$ (c 1.04, H₂O) (lit.^[42] mp 195–197 °C, $[\alpha]_D^{20} +68.6$ (c 1, H₂O)). ^1H NMR (DMSO-*d*₆): 3.56 (br m, 1H), 3.82 (br s, 1H), 3.92 (br s, 1H), 4.15 (br d, $J = 6.5$, 1H), 4.39 (br s, 1H), 4.71 (br s, 1H), 4.91 (br s, 1H), 5.00 (br s, 1H), 5.10 (br s, 1H), 5.28 (br s, 1H). ^{13}C NMR (DMSO-*d*₆): 71.1 (CH), 73.3 (CH), 73.6 (CH), 74.2 (CH), 75.7 (CH), 208.0 (C). HRMS–ESI m/z : $[\text{M} + \text{Na}]^+$ calcd for C₆H₁₀NaO₆, 201.0370; found, 201.0378. ^1H and ^{13}C NMR were in good agreement with those reported.^[42]

D-chiro-Inositol: To a solution of *chiro*-**3a** (195 mg, 0.362 mmol) in MeOH (2 mL), was added 10% Pd/C (wetted with 55% water, 193 mg, 0.0819 mmol), and the mixture was stirred under H₂ atmosphere at rt for 10 h. After addition of H₂O (5 mL), the whole was filtered through filter paper, which was washed with H₂O (5 mL × 3). The combined filtrate was concentrated *in vacuo* to give the title compound (53 mg, 81%) as a slightly brown solid of mp 231–235 °C (H₂O/EtOH) with $[\alpha]_D^{20} +65.2$ (c 1.05, H₂O) (lit.^[42] $[\alpha]_D^{24} +85.5$ (c 0.1, H₂O);^[54] mp 238–242 °C, $[\alpha]_D^{20} +63.2$ (c 1, H₂O)^[42]). ^1H NMR (D₂O): 3.52 (m, 2H), 3.70 (m, 2H), 3.96 (br s, 2H). ^{13}C NMR (D₂O): 71.0 (CH), 72.3 (CH), 73.3 (CH). HRMS–ESI m/z : $[\text{M} + \text{Na}]^+$ calcd for C₆H₁₂NaO₆, 203.0526; found, 203.0532. ^1H and ^{13}C NMR were in good agreement with those reported.^[54,42]

Acknowledgements

We thank Hiroki Konegawa for his contribution in the preliminary study. We thank JSPS [Grant-in-Aid for Young Scientist (B)]; MEXT (Grant-in-Aid for Scientific Research on Innovative Areas “Advanced Molecular Transformations by Organocatalysts” and Platform for Drug Design, Discovery and Development); and Takeda Science Foundation for financial support.

References

- [1] Selected examples: a) Inoue, S. *J. Pharm. Soc. Jpn.* **1987**, 107, 645. b) Chida, N.; Yamada, K.; Ogawa, S. *Chem. Lett.* **1992**, 687. c) Chida, N.; Yoshinaga, M.; Tobe, T.; Ogawa, S. *Chem. Commun.* **1997**, 1043. d) Suzuki, T.; Suzuki, S. T.; Yamada, I.; Koashi, Y.; Yamada, K.; Chida, N. *J. Org. Chem.* **2002**, 67, 2874. e) Li, M.; Wu, A.; Zhou, *Tetrahedron Lett.* **2006**, 47, 3707. Review: f) Kiddle, J. J. *Chem. Rev.* **1995**, 95, 2189.
- [2] a) Schopfer, W. H.; Posternak, T. *Helv. Chim. Acta*, **1960**, 43, 2147. b) Nestler, J. E.; Jakubowicz, D. J.; Reamer, P.; Gunn, R. D.; Allan G. N. *Engl. J. Med.* **1999**, 17, 1314. c) Palatnik, A.; Frolov, K.; Fux, M.; Benjamin, J. *J. Clin. Psychopharmacol.* **2001**, 21, 335. d) McLaurin, J.; Kierstead, M. E.; Brown, M. E.; Hawkes, C. A.; Lambermon, M. H. L.; Phinney, A. L.; Darbie, A. A.; Cousins, J. E.; French, J. E.; Lan, M.

- F.; Chen, F.; Wong, S. S. N.; Mount, H. T. J.; Fraser, P. E.; Westaway, D.; George-Hyslop, P. S. *Nat. Med.* **2006**, *12*, 801.
- [3] a) Duchek, J.; Adams, D. R.; Hudlicky, T. *Chem. Rev.* **2011**, *111*, 4223. b) Arjona, O.; Gómez, A. M.; López, J. C.; Plumet, J. *Chem. Rev.* **2007**, *107*, 1919.
- [4] a) Carless, H. A. J. *Tetrahedron: Asymmetry* **1992**, *3*, 795. b) Hudlicky, T.; Gonzalez, D.; Gibson, D. T. *Aldrichimica Acta* **1999**, *32*, 35. c) Paul, B. J.; Willis, J.; Martinot, T. A.; Ghiviriga, I.; Abboud, K. A.; Hudlicky, T. *J. Am. Chem. Soc.* **2002**, *124*, 10416. d) S. Pilgrim, G. Kociok-Köhn, M. D. Lloyd and S. E. Lewis, *Chem. Commun.* **2011**, 47, 4799. e) Griffen, J. A.; White, J. C.; Kociok-Köhn, G.; Lloyd, M. D.; Wells, A.; Arnot, T. C.; Lewis, S. E. *Tetrahedron* **2013**, *69*, 5989.
- [5] a) Ferrier, R. J. *J. Chem. Soc., Perkin Trans. 1*, **1979**, 1455. b) Machado, A. S.; Olesker, A.; Lukacs, G. *Carbohydr. Res.* **1985**, *135*, 231. c) Chida, N.; Ohtsuka, M.; Ogura, K.; Ogawa, S. *Bull. Chem. Soc. Jpn.* **1991**, *64*, 2118. d) Adam S. *Tetrahedron Lett.* **1988**, *29*, 6589. e) László, P.; Dudon, A.; *J. Carbohydr. Chem.* **1992**, *11*, 587. f) Takahashi, H.; Kittaka, H.; Ikegami, S. *J. Org. Chem.* **2001**, *66*, 2705. g) Das, S. K.; Mallet, J.-M.; Sinaÿ, P. *Angew. Chem. Int. Ed. Engl.* **1997**, *36*, 493. h) Sollogoub, M.; Mallet, J.-M.; Sinaÿ, P. *Tetrahedron Lett.* **1998**, *39*, 3471.
- [6] a) Suami, T.; Tadano, K.; Kameda, Y.; Iimura, Y. *Chem. Lett.* **1984**, 1919. b) Tadano, K.; Maeda, H.; Hoshino, M.; Iimura, Y.; Suami, T. *J. Org. Chem.* **1987**, *52*, 1946.
- [7] Yoshikawa, M.; Cha, B. C.; Nakae, T.; Kitagawa, I. *Chem. Pharm. Bull.* **1988**, *36*, 3714.
- [8] Andersson, F. O.; Classon, B.; Samuelsson, B. *J. Org. Chem.* **1990**, *55*, 4699.
- [9] a) Bräuer, N.; Dreeßen, S.; Schaumann, E. *Tetrahedron Lett.* **1999**, *40*, 2921. b) Le Merrer, Y.; Gravier-Pelletier, C.; Maton, W.; Numa, M.; Depezay, J.-C. *Synlett* **1999**, 1322.
- [10] a) Tatsuta, K.; Mukai, H.; Takahashi, M. *J. Antibiot.* **2000**, *53*, 430. b) Rassu, G.; Auzzas, L.; Pinna, L.; Battistini, L.; Zanardi, F.; Marzocchi, L.; Acquotti, D.; Casiraghi, G. *J. Org. Chem.* **2000**, *65*, 6307.
- [11] a) Paulsen, H.; von Dein, W. *Liebigs Ann. Chem.* **1987**, 125. b) Fukase, H.; Horii, S. *J. Org. Chem.* **1992**, *57*, 3651. c) Cai, S.; Stroud, M. R.; Hakomori, S.; Toyokuni, T. *J. Org. Chem.* **1992**, *57*, 6693.
- [12] a) Watanabe, Y.; Mitani, M.; Ozaki, S. *Chem. Lett.* **1987**, 123. b) Chiara, J. L.; Martín-Lomas, M. *Tetrahedron Lett.* **1994**, *35*, 2969. c) Carpintero, M.; Fernández-Mayoralas, A.; Jaramillo, C. *J. Org. Chem.* **1997**, *62*, 1916. d) Carpintero, M.; Jaramillo, C.; Fernández-Mayoralas, A. *Eur. J. Org. Chem.* **2000**, 1285.
- [13] Kapferer, P.; Sarabia, F.; Vasella, A. *Helv. Chim. Acta* **1999**, *82*, 645.
- [14] a) McCasland, G. E.; Furuta, S.; Durham, L. J. *J. Org. Chem.* **1966**, *31*, 1516. b) Shing, T. K. M.; Elsley, D. A.; Gillhouley, J. G. *J. Chem. Soc., Chem. Commun.* **1989**, 1280. c) Tatsuta, K.; Niwata, Y.; Umezawa, K.; Toshima, K.; Nakata, M. *Tetrahedron Lett.* **1990**, *31*, 1171. d) Ishikawa, T.; Shimizu, Y.; Kudoh, T.; Saito, S. *Org. Lett.* **2003**, *5*, 3879.
- [15] Sudha, A. V. R. L.; Nagarajan, M. *Chem. Commun.* **1998**, 925.
- [16] Originally reported as a cyanide-catalyzed reaction: a) Lapworth, A. J. *J. Chem. Soc.* **1903**, 20, 995. b) Lapworth, A. J. *J. Chem. Soc.* **1904**, 21, 1206.
- [17] a) Ukai, T.; Tanaka, R.; Dokawa, S. *J. Pharm. Soc. Jpn.* **1943**, *63*, 296. b) Breslow, R. *J. Am. Chem. Soc.* **1958**, *80*, 3719.
- [18] Reviews on NHC catalysis: a) Enders, D.; Niemeier, O.; Henseler, A. *Chem. Rev.* **2007**, *107*, 5606. b) Bugaut, X.; Glorius, F. *Chem. Soc. Rev.* **2012**, *41*, 3511. c) Vora, H. U.; Wheeler, P.; Rovis, T. *Adv. Synth. Catal.* **2012**, *354*, 1617. d) Chen, X.-Y.; Ye, S. *Synlett* **2013**, 24, 1614. e) Ryan, S. J.; Candish, L.; Lupton, D. W. *Chem. Soc. Rev.* **2013**, *42*, 4906. f) Mahatthananchai, J.; Bode, J. W. *Acc. Chem. Res.* **2014**, *47*, 696.
- [19] a) Hachisu, Y.; Bode, J. W.; Suzuki, K. *J. Am. Chem. Soc.* **2003**, *125*, 8432. b) Hachisu, Y.; Bode, J. W.; Suzuki, K. *Adv. Synth. Catal.* **2004**, *346*, 1097. c) Enders, D.; Niemeier, O. *Synlett* **2004**, 2111. d) Enders, D.; Niemeier, O.; Balensiefer, T. *Angew. Chem. Int. Ed.* **2006**, *45*, 1463. e) Enders, D.; Niemeier, O.; Raabe, G. *Synlett* **2006**, 2431.
- [20] a) Takikawa, H.; Hachisu, H.; Bode, J. W.; Suzuki, K. *Angew. Chem. Int. Ed.* **2006**, *45*, 3492. b) Takikawa, H.; Suzuki, K. *Org. Lett.* **2007**, *9*, 2713.
- [21] Mennen, S. M.; Miller, S. J. *J. Org. Chem.* **2007**, *72*, 5260.
- [22] Cookson, R. C.; Roger, M. L. *J. Chem. Soc., Chem. Commun.* **1976**, 20, 804.
- [23] Mennen, S. M.; Miller, S. J. *J. Org. Chem.* **2007**, *72*, 5260.
- [24] Inositol synthesis with benzoin-type cyclization has recently been reported: Stockton, K. P.; Greatrex, B. W.; Taylor, D. K. *J. Org. Chem.* **2014**, *79*, 5088.
- [25] Stetter, H.; Kuhlmann, H. *Angew. Chem. Int. Ed. Engl.* **1976**, *15*, 639.
- [26] In contrast to comments in ref 24, decomposition of **2a** was not observed during silica gel chromatography.
- [27] Karplus, M. *J. Am. Chem. Soc.* **1963**, *85*, 2870.
- [28] Kerr, M. S.; Read de Alaniz, J.; Rovis, T. *J. Org. Chem.* **2005**, *70*, 5725.
- [29] Sohn, S. S.; Bode, J. W. *Org. Lett.* **2005**, *7*, 3873.
- [30] Dudding, T.; Houk, K. N. *Proc. Natl. Acad. Sci.* **2004**, *101*, 5770.
- [31] White, N. A.; DiRocco, D. A.; Rovis, T. *J. Am. Chem. Soc.* **2013**, *135*, 8504.

- [32] Iida, T.; Chang, F. C. *J. Org. Chem.* **1983**, *48*, 1194.
- [33] Narasaka, K.; Ukaji, Y.; Ysmazaki, S. *Bull. Chem. Soc. Jpn.* **1986**, *59*, 525.
- [34] Herscovici, J.; Egron, M.-J.; Antonakis, K. *J. Chem. Soc., Perkin Trans. 1*, **1988**, 1219.
- [35] Vora, H. U.; Lathrop, S. P.; Reynolds, N. T.; Kerr, M. S.; Read de Alaniz, J.; Rovis, T. *Org. Synth.* **2010**, *87*, 350.
- [36] Mabiala-Bassiloua, C.-G.; Zwolinska, M.; Therisod, H. Sygusch, J.; Therisod, M. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 1735.
- [37] Guidot, J. P.; Le Gall, T.; Mioskowski, C. *Tetrahedron Lett.* **1994**, *35*, 6671.
- [38] Painter, G. F.; Eldridge, P. J. Falshaw, A. *Bioorg. Med. Chem.* **2004**, *12*, 225.
- [39] Migaud, M. E.; Frost, J. W. *J. Am. Chem. Soc.* **1995**, *117*, 5154.
- [40] Bruzik, K. S.; Salamończyk, G. M. *Carbohydr. Res.* **1989**, *195*, 67.
- [41] Jagdhane, R. C.; Patil, M. T.; Krishnaswamy, S. Shashidhar, M. S. *Tetrahedron* **2013**, *69*, 5144.
- [42] Mandel, M.; Hudlicky, T. *J. Org. Chem.* **1993**, *58*, 2331.